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Amylin is a 37 amino acid long peptide that aggregates into toxic oligomers and fibrils. Since 
amylin is secreted by and also acts on pancreatic beta cells, type II diabetes is classified as an 
amyloidogenic disease. This study focuses on the development of a cost effective chemical 
synthetic strategy for amylin synthesis as previous studies relied on extremely expensive 
pseudoproline derivatives. Furthermore, commercially available amylin varies between 
batches and also contains impurities that could generate anomalies and affect reproducibility 
of experiments. Secondly, chemically synthesized non-methylated and N-methylated 
derivatives of amylin were shown to inhibit toxicity of full length amylin. A fluorescently-
labeled chemically synthesized derivative of amylin was used to track cellular localization of 
amylin via confocal microscopy. Amylin aggregation kinetics was established using a surface 
plasmon resonance (SPR) biosensor. In addition, nanoparticle tracking analysis (NTA) was 
used as a novel technique to determine the size of oligomers over real time. This technology 
indicated that the size range of the toxic species of amylin is between 200-300 nm. 
Furthermore, it can be suggested that NTA could potentially be developed into a screening 
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Chapter 1  Introduction and Project Aims 
 
2 
1. INTODUCTION AND PROJECT AIMS 
 
1.1 INTRODUCTION 
Type II diabetes is a debilitating disease that is associated with numerous secondary medical 
complications. It is remarkable that more than a century ago a link was established between 
the deposition of fibrillar material in the pancreas and manifestation of this disease.[1] The 
fibrillar material was found to be composed of amylin, a 37 amino acid polypeptide, and thus 
type II diabetes was classified as an amyloid disease.[2, 3] 
 
Amylin is released together with insulin from pancreatic beta cells and it has been suggested 
that a high carbohydrate/fat diet results in increased insulin secretion, which is coupled to a 
concomitant increase in amylin secretion.[4, 5] This monomeric form of amylin can then 
aggregate into oligomeric and fibrillar β-sheet structures, the former of which has been 
observed to impose toxicity to pancreatic beta cells.[6-9] 
 
In view of the above, a range of molecules were evaluated as potential inhibitors of amylin-
mediated aggregation and which could be subsequently employed to prevent aggregated 
amylin-induced cytotoxicity. Polycyclic compounds were shown to be efficient inhibitors of 
amylin aggregation and were also found to reduce cytotoxicity. These compounds include 
Congo red, resveratrol and tetracycline and it has been suggested that heteroaromatic 
interactions between these molecules and amylin result in geometric constraints that prevent 
fibrillogenesis.[10-14] Peptide-based inhibitors which are homologous to distinct regions of 
the amino acid sequence of amylin were also evaluated as potential inhibitors. 
Peptidomimetics incorporating N-methylated amino acids were also assessed as likely 
inhibitor candidates as they would facilitate disruption of the hydrogen bonding capacity of 
amylin and thereby prevent formation of β-sheet structures. An amylin derivative of full 
length amylin with N-methylated amino acids at residues 24 and 26, amylin22-27 with N-
methylated amino acids at residues 23 and 25, amylin13-18 and amylin20-25 were found to 
significantly decrease amylin cytotoxicity.[15-18] However, despite patents being granted on 
some of the above mentioned derivatives, none of them have been used in clinical trials.[19, 
20] Moreover, short peptides spanning the length of amylin are yet to be evaluated for their 
inhibitory effect on amylin-mediated cytotoxicity. In view of the above, the development of 
peptide- and peptidomimetic therapeutics against amylin aggregation is an attractive research 
niche. 
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Some of the techniques used to monitor amylin aggregation are circular dichroism, Fourier 
transform infrared (FT-IR) spectroscopy, transmission electron microscopy (TEM), atomic 
force microscopy (AFM), the thioflavin T (ThT) assay and the sedimentation assay.[6, 7, 21-
25] However, with the exception of AFM, none of the techniques are able to identify the 
oligomeric species of amylin and thus cannot be used as a screening method for potential 
inhibitors of amylin-mediated cytotoxicity. In addition, AFM is labor-intensive and samples 
must be adsorbed to a mica surface in order to monitor fibril growth over time which is a 
cause for concern since it has been reported that the type of amylin fibrils that form in the 
presence of a mica surface is significantly different in morphology from that formed free in 
solution.[26, 27] Currently, the mammalian cell line-based cytotoxicity assay is the preferred 
strategy when screening for potential therapeutic agents against amylin aggregation-induced 
type II diabetes.[11, 15-17, 28-37] Although this assay yields quantitative data with regard to 
the protective potential of compounds, it is very expensive and time-consuming as it is 
dependent on the growth rate of a particular mammalian cell line. Consequently, there exists a 
need for the development of a cell-free strategy that would allow efficient screening of 
potential inhibitors of amylin-mediated cytotoxicity. 
 
In addition, the cytotoxicity assay is dependent on the use of full length human amylin. 
However, the isolation and purification of human amylin from biological resources is 
extremely expensive. Moreover, the hydrophobic nature of the peptide makes it a challenging 
entity to chemically synthesize, and currently available synthetic procedures for full length 
human amylin make use of very expensive pseudoproline derivatives.[38-43] Of note, it was 
reported that commercially available amyloidogenic peptides from manufacturers have 
differing fibrillogenic properties.[44] Thus, to enable extensive amylin-based research, a cost-
effective synthetic strategy for full length human amylin should be developed.  
 
Moreover, for effective design of potential therapeutic agents of type II diabetes that would 
act by preventing amylin-cell interactions, an in-depth insight into the cellular localization of 
amylin would be highly beneficial. Although previous studies have been performed that sheds 
some light on amylin localization, all studies to date have made use of an indirect fluorescent 
labeling approach.[45-47] Amongst other dyes, Congo red has been used to identify amylin 
aggregates. However, Congo red was demonstrated to bind non-specifically to cellular 
membranes [47] and it was also found to decrease both the rate of amylin fibrillogenesis and 
its cytotoxic effect.[11, 13] It can thus be suggested that use of an indirect labeling approach 
would affect amylin-amylin and amylin-cell interactions thereby complicating data 
interpretation. A direct fluorescent labeling approach is therefore necessary to cellular localize 
amylin via fluorescent microscopy.  
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1.2 SCOPE OF THESIS AND AIMS OF STUDY 
The main aim of this study was to synthesize and evaluate the aggregation dynamics of 
amylin. This thesis is divided into seven chapters, including this introduction (Chapter 1). 
 
In Chapter 2, a comprehensive literature review encompassing the molecular dynamics of 
amylin aggregation, proposed mechanisms of amylin-mediated cytotoxicity, techniques used 
to monitor amylin aggregation and toxicity, inhibitors of amylin-mediated cytotoxicity and 
synthetic strategies for amylin are presented. This chapter has been accepted for publication in 
Journal of Biomedicine and Biotechnology. 
 
In Chapter 3, different coupling conditions and oxidation methods were evaluated in an 
attempt to develop a cost effective, microwave-assisted solid-phase peptide synthetic strategy 
for production of amylin. The fibrillogenic and cytotoxic properties of chemically synthesized 
amylin was also ascertained to establish its suitability as a substitute for naturally occurring 
amylin. This aspect of the study was reported in the journal Peptide Science.[44] 
 
With a cost effective chemical synthetic strategy for amylin production in place, attention 
switched to synthesis and evaluation of amylin derivatives as potential inhibitors of amylin 
aggregation and its resultant cytotoxicity which are described in Chapter 4. Five peptide 
derivatives spanning the length of amylin and their N-methylated counterparts were 
synthesized using a microwave-assisted solid-phase strategy. These amylin derivatives were 
co-incubated with chemically synthesized full length human amylin (Chapter 1), and 
transmission electron microscopy (TEM) analysis was performed to assess the effect of each 
of the amylin derivatives on amylin fibrillogenesis. The potential of each amylin derivative as 
an inhibitor of amylin-mediated toxicity was also evaluated using a mammalian cell line-
based cytotoxicity assay. This aspect of the research study was published in Bioorganic and 
Medicinal Chemistry Letters.[48] 
 
Chapter 5 describes the suitability of surface plasmon resonance (SPR), dynamic light 
scattering (DLS), and nanoparticle tracking analysis (NTA) as cell-free systems for 
monitoring amylin aggregation and for screening potential inhibitors of amylin-mediated 
cytotoxicity. Each technique was used to monitor amylin aggregation dynamics, and only 
SPR and NTA were observed to generate useful data. The SPR technique yielded quantitative 
association and dissociation kinetics of amylin whilst NTA shed light on the size of amylin 
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aggregates that developed over real time. The latter two techniques were then employed to 
monitor changes in amylin aggregation dynamics that arose as a consequence of co-
incubating amylin with each of its derivatives that were synthesized in Chapter. 4. The 
potential of SPR and NTA as screening tools for amylin-mediated cytotoxicity was evaluated 
by comparison of this data set to earlier cytotoxicity results (Chapter 4) 
 
In Chapter 6, the cellular localization of amylin was studied using imaging of in vitro cell 
cultures. Full length human amylin bearing a carboxyfluorescein group on the N-terminus was 
chemically synthesized and used in confocal microscopy investigations to establish the 
cellular localization of the fluorescently-labeled amylin. The novelty aspect of this study is 
that a direct labeling approach was utilized, thus negating any impact that external dyes may 
have on amylin aggregation kinetics or amylin-cell interactions. This aspect of the research 
study has been accepted for publication in Biotechnology and Applied Biochemistry. 
 
Finally, Chapter 7 presents a general conclusion and ideas on future research concepts. 
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2 LITERATURE REVIEW 
 
2.1 Introduction 
As mused by Reynaud (2010), “as our life expectancy increases, the chances of getting a 
degenerative disease also increases…caused by something conceptually quite 
simple…incorrect protein folding.”[1] There are currently more than a dozen protein 
misfolding diseases which have been classified as amyloid diseases, with an equivalent 
number of amyloidogenic proteins responsible for each of them.[2] The amyloid diseases 
include Alzheimer’s disease [3-9], Parkinson’s disease [10, 11], Huntington’s disease [11], 
Prion disease [12], primary and secondary systemic amyloidosis [2], and type II diabetes [13-
18] for which the responsible misfolded protein is amyloid beta (Aβ), huntingtin, α-synuclein, 
prion protein (PrP), immunoglobulin (Ig) light chain, serum amyloid A, and amylin 
respectively. Other than Alzheimer’s disease, type II diabetes is the most prevalent in modern 
society with currently 346 million diabetic people world-wide and the World Health 
Organization (WHO) predicts that the number of deaths that result from this disease will 
double between 2005 and 2030.[19] Type II diabetes is responsible for a number of secondary 
complications such as heart attack, stroke, blindness and renal failure [20] and thus research 
on amylin is of paramount importance in the fight against this debilitating disease. 
 
Amylin, also referred to as islet amyloid polypeptide (IAPP), is composed of 37 amino acid 
residues and as seen in Figure 2.1 contains a disulfide bridge between residues two and seven. 
 
K C N T A T C A T Q R L A N F L V H S S N N F G A I L S S T N V G S N T Y
1 10 20 30 37
Figure 2.1 Amino acid sequence of amylin. Redrawn from Cooper et al. (1987).[21]  
 
Amylin is produced after an 89-amino acid long precursor protein referred to as preProIAPP 
is cleaved at the N-terminal yielding ProIAPP and which is subsequently post-translationally 
processed by the prohormone convertase (PC2).[22] These processes occur in pancreatic beta 
cells and hence amylin is secreted together with insulin in a 20 to 1 molar ratio of insulin to 
amylin.[23] Insulin is released following a diet rich in carbohydrates, as it is the hormone 
responsible for lowering blood glucose levels. Insulin functions by the following strategies; 
stimulation of mainly the muscle cells and adipocytes to increase their uptake of glucose, 
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activation of enzymes responsible for glucose metabolism, increasing conversion of glucose 
to glycogen, and inhibiting protein and lipid breakdown and stimulating their synthesis.[20] 
Initially, it was reported that amylin works antagonistically to insulin by inhibiting 
glycogenesis and promoting glycolysis.[24-27] However, other studies have suggested that 
amylin plays a critical role in glucose homeostasis by suppressing the release of glucagon 
from pancreatic alpha cells, and hence prevents release of glucose from the liver, decreases 
gastric emptying and stimulates the satiety center in the brain.[23, 28-31] The latter two 
events are important features that prevent an individual from feeling hungry thereby averting 
the condition of having even more stored glucose being released into the blood. Since amylin 
is co-released with insulin, consuming an excess amount of carbohydrates and fat may lead to 
an elevated amount of amylin being secreted that could eventually initiate amylin 
aggregation, since it was found that a high carbohydrate or high fat diet promoted amyloid 
formation in transgenic mice.[32, 33] 
 
Amylin aggregation has been suggested to occur in a step-wise manner, with soluble 
monomeric amylin forming oligomeric structures, protofibrils and eventually amyloid fibrils, 
some of which are toxic to the pancreatic beta cells.[34] Destruction of the pancreatic beta 
cells results in decreased insulin production, and manifests as type II diabetes, a condition that 
is characterized by excess extracellular glucose with an intracellular deficit. The most 
commonly used treatment for diabetes is metformin and insulin. Although these two 
therapeutic agents help to manage the disease, they do not stop progression nor do they cure 
this debilitating disease. 
 
An extensive review on amylin was conducted more than a decade ago by Kapurniotu (2001) 
which focused primarily on the morphological and structural features of amylin aggregates, 
mechanism of aggregation, and the effects of amylin on cell viability with a brief over-view 
on the potential of N-methylated peptides as inhibitors of amylin-mediated cytotoxicity.[13] 
More recently, two extensive reports on amylin have been published. One of the review 
articles focuses on the structural characteristics of amylin, mechanisms of its aggregation, 
factors affecting aggregation, and touched briefly on mechanisms of toxicity and inhibitors of 
aggregation [17], whilst the other gave a very insightful overview of the physiological and 
pathophysiological role of amylin, the toxic species of amylin and briefly highlighted a 
potential mechanism of amylin pathogenesis.[18] 
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This literature review aims to provide an in-depth and up-to-date over-view of the molecular 
mechanism of amylin aggregation, all possible mechanisms of amylin-mediated toxicity, 
commonly used techniques for evaluating inhibitors of fibril formation and toxicity, 
compounds that have been tested as potential inhibitors of amylin-mediated cytotoxicity, as 
well as a brief overview of the chemical strategies that are used to synthesize amylin. 
 
2.2 Molecular mechanism of amylin aggregation 
As amylin aggregation is central to this peptide acquiring cytotoxic properties, numerous 
researchers have over the last two decades either observed or proposed the molecular 
mechanism and region responsible for amylin aggregation (Table 2.1), with a common feature 
among all studies being that the aggregates are in a β-sheet conformation. The first study on 
the amyloidogenic region of amylin was performed by Westermark et al. (1990) and based on 
the non-amyloidogenic nature of amylin from different species and experimental data using 
synthetic peptides, proposed that the 25-29 region is the shortest amyloidogenic region of 
amylin.[35] With the exception of the 1-7 region of amylin, the entire length of this peptide 
has at some stage been shown to have amyloidogenic properties (Table 2.1). Of note, it was 
found that the 22-27 region coiled around each other into typical amyloid fibrils [36] and also 
increased fibril formation.[37] In addition, the 11-20 region was found to bind to amylin with 
the highest affinity when compared to peptides that were homologous to other regions of 
amylin and the 14-18 region was suggested to be the core recognition site for amylin 
binding.[38] 
 
One of the earliest models for β-sheet formation was proposed by Jaikaran et al. (2001) 
(Figure 2.2A).[39] According to this model, β-turns are predicted at residue 31 thereby 
allowing the 24-29 and 32-37 regions to form an anti-parallel β-sheet, and at residue 20 which 
would allow the 18-23 region to extend the β-sheet.[39] This model also proposes that 
hydrophobic interactions are responsible for initiating the aggregation process and that 
hydrogen bonds stabilizes the β-sheet structure.[39] A later study proposed that the 12-17, 22-
27 and 31-37 regions form anti-parallel β-sheets with the 18-21 and 28-30 regions forming the 
β-turns (Figure 2.2B).[40] In addition, it was also suggested that the hydrophobic side chains 
in the 15-17 and 32 region interacts with that of the 23-27 region whilst there is inter-strand 
hydrophilic association between the 28-31 regions of amylin (Figure 2.2C).[41] It is 
noteworthy that there is considerable overlap between the β-sheet forming regions proposed 
by all three model-predicting studies. In addition, the predicted β-sheet forming regions 
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contains the proposed nucleation sites for aggregation [42] as well as aromatic amino acids 
which have been reported to play a significant role in amyloid formation due to interactions 
between the planar aromatic structures which are also referred to as π-π interactions.[43] 
Taking all models into consideration, a proposed model of the β-sheet and β-turn regions of 
amylin is illustrated in Figure 2.2D. This model proposes that the 12-17, 23-27, and 32-37 
regions make up the β-sheet structure with regions 20-21 being constituents of the β-turn 
region. Residues 18, 19, 22, and 28-31 could participate in forming either the β-sheet or β-
turn. 
 
Table 2.1 Observed and predicted amyloid forming regions of amylin 
Year Amyloidogenic region Predicted or Observed 
1990[35] 20-29 Observed 
1999[44] 17-34, 24-37, 30-37 Observed 
2000[45] 20-29 Observed 
2000[36] 23-27 and 22-27 Observed 
2001[46] 22-29 Observed 
2001[39] 8-20 Observed 
2002[38] 14-18, 14-22, 14-20, 15-20, 15-19 Observed 
2002[37] 22-27 Observed 
2003[47] 12-17, 15-20 Observed 
2005[40] 12-17, 22-27, 31-37 Observed 
2006[48] 13-18 Predicted 
2007[41] 8-17, 28-37 Predicted 
2007[49] 12-18, 15-20, 22-28 Predicted 
2009[42] 8, 13, 17, 25, 27, 32* Predicted 
* Nucleation sites 
 
 




Figure 2.2 Schematic representation of the β-sheet and β-turn regions of amylin as predicted 
by (A) Jaikaran et al. (2001), (B) Kajava et al. (2005), and (C) Luca et al. (2007).[39-41] 
Data integration for a comprehensive understanding of previous predictions (A, B and C) is 
illustrated in D. 
 
Thus, soluble monomeric amylin can associate into soluble β-sheet oligomeric states [50] 
which further progresses to protofibrils and insoluble amyloid fibrils.[51] According to 
Kodali et al. (2007), the oligomer which is formed prior to the protofibril is defined as being a 
“…metastable multimer in an amyloid formation reaction.”[34] These soluble intermediates 
were reported to have diameters between 2.7-4 nm whilst protofibrils have a width of 5 nm 
and are “…non-spherical filamentous structures lacking a periodic substructure that are often 
found at intermediate times during the formation of mature fibrils,” and amyloid fibrils, are 
“…relatively straight, unbranched protein fibrils, with diameters in the 10 nm range, and 
often (but not always) consist of multiple protofilaments twisted around the fibril axis” 
(Figure 2.3).[34, 52]  
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Analysis of amyloid fibrils has revealed that individual β-strands are orientated perpendicular 
to the long fiber axis and thus form β-sheets.[53-56] Research studies by Goldsbury et al. 
(1999), revealed that amylin fibrils grow bidirectionally at a rate of approximately 1.1 nm per 
minute and that the width of fibrils ranged between 6-8 nm.[52] Thus, there is still no 
conclusively accepted size of each of the different types of amylin aggregates.  
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2.3 Mechanism of Amylin Toxicity 
Previously there was general acceptance that the fibrillar form of amylin is the toxic species 
[58-66], however the more recent consensus is that the soluble oligomeric structures exert the 
toxic effect.[67-73] Two noteworthy experiments for the latter hypothesis were conducted in 
2006 and 2010.[73, 74] Meier et al. (2006) evaluated rifampicin as a potential inhibitor of 
type II diabetes and found that although it did prevent fibril formation, toxicity of amylin was 
still present, thus concluding that the soluble oligomers are the toxic species.[74] The second 
study showed that the fibrillar species of amylin was positively correlated with longevity of 
transgenic mice, once again suggesting that the prefibrillar or oligomeric form is toxic.[73] 
Although there is currently a general acceptance that the oligomeric form of amylin is the 
toxic species, there are numerous theories regarding its mechanism of cytotoxicity.  
 
The first mechanism of toxicity postulated is membrane disruption and subsequent 
disturbance of intracelluar homeostasis. It was initially reported by Westermark et al. (1990) 
that amylin disrupts cell membranes thereby causing cell death.[35] Thereafter Lorenzo et al. 
(1994) exposed islet cells sandwiched between coverslips as well as unprotected cells to 
human amylin aggregates and found using Nomarsky microscopy that amylin interaction with 
the cell membrane was crucial for toxicity.[75] Subsequent studies supported this theory by 
demonstrating that amylin aggregates formed pores or channels in lipid bilayers.[59, 68, 69, 
76] Planar phospholipid bilayer membranes were used to demonstrate that non-selective ion 
voltage-dependent channels were formed in the presence of amylin.[59] This will promote the 
influx of Ca2+ and Na+, and K+ efflux, thereby disrupting ionic homeostasis.[59] Kayed et al. 
(2004) also employed lipid bilayers and showed that there was increased conductance in the 
presence of amylin oligomers and fibrils.[69] In addition, intracellular calcium levels were 
found to be elevated after exposure to amylin and it is noteworthy that destabilization of 
intracellular Ca2+ homeostasis was a mechanism used by other amyloidogenic peptides to 
induce toxicity.[58, 77]  
 
Subsequent studies also demonstrated that fibril formation was increased in the presence of 
anionic lipid membranes.[55, 78] and it was suggested that electrostatic interactions between 
amylin and the negatively charged lipids on membranes are responsible for amylin association 
with the cell membrane.[79] In addition, amylin was found to insert into plasma membranes 
and incorporated membrane lipids into the growing amyloid fibril, thereby causing membrane 
disruption.[79-82] Using human islets and amylin oligomers, Ritzel et al. (2007) 
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demonstrated that amylin oligomers could promote the loss of rat pancreatic β-cells 
(RINm5F) by disrupting the cell membrane as well as the islet achitecture such as cell-to-cell 
adherence, both of which are crucial for cell survival.[72] Reviews by Engel and coworkers 
(2008 and 2009) extensively describe amylin-mediated membrane disruption [16, 83] and it 
thus appear that membrane disruption could be a leading cause of amylin-mediated toxicity. 
 
The second proposed mechanism of amylin-mediated toxicity is generation of reactive 
oxygen species (ROS) such as hydrogen peroxide (H2O2), which results in cell death.[58] 
ROS are able to damage DNA, and oxidizes the constituent amino acids of proteins as well as 
polyunsaturated fatty acids that are present in lipids, all of which can lead to apoptosis. ROS 
damages DNA by causing strand breakage, base modification, oxidation of deoxyribose, and 
DNA-protein cross-links.[84] Since cell membranes are made up of a large amount of 
polyunsaturated fatty acids, oxidation by ROS causes harmful changes in membrane fluidity, 
permeability and metabolic functions. Oxidative damage to proteins results in either protein 
degradation or alteration of its properties such as causing a soluble protein to aggregate, both 
of which are detrimental to cell survival.[84] It was also shown that generation of ROS was a 
mechanism used by other amyloidogenic peptides for toxicity.[58] At the same time, Schubert 
et al. (1995) detected peroxides using 2',7'-dichlorofluorescin diacetate and also demonstrated 
that amylin increased the accumulation of H2O2 in B12 cells.[85]  
 
The third hypothesis of amylin-mediated toxicity is apoptosis. Apoptosis is defined as 
programmed cell death and is characterised by cell shrinkage, membrane blebbing 
(detachment of the cell membrane from the cytoskeleton), disruption of nuclear architecture 
and DNA laddering (breaking of chromosomal DNA into fragments containing 180 base 
pairs).[86] 
 
In early experiments, Lorenzo et al. (1994) showed that aurintricarboxylic acid, an 
endonuclease inhibitor that stops apoptosis, is able to reduce amylin-mediated toxicity of islet 
cells.[75] They had also stained islet cells with propidium iodide and with the aid of 
epifluorescence microscopy showed that there was chromatin condensation.[75] In addition, 
agarose gel electrophoresis revealed that DNA fragmentation had also occurred.[75]  
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Thereafter the TUNEL assay and gel electrophoresis was employed to reveal that amylin 
triggered DNA fragmentation and apoptosis in RINm5F cells.[87] This research team also 
used quantitative Northern blot analysis to demonstrate that amylin increased expression of 
the p21 and p53 tumor suppressor genes, both of which encode for proteins that arrest cell 
proliferation, leading to apoptosis (Figure 2.4).[87] This finding was later supported by 
transmission electron microscopy (TEM) and scanning electron microscopy (STEM) analysis 
of RINm5F cells that were exposed to amylin which clearly illustrated ultra-structural 
evidence of apoptotic damage.[88] The theory that apoptosis is the mechanism by which 
amylin causes cell death was further supported by the finding that amylin increases the 
expression of c-Jun, a gene that is involved in the apoptotic pathway (Figure 2.4), in RINm5F 
and the human insulinoma cell line (CM).[89] Moreover, it was reported that amylin could 
elevate the levels of Fas ligand (FasL) and Fas-associated death domain (FADD) [90], both of 
which are involved in apoptosis (Figure 2.4), and Huang et al. (2007) demonstrated that 
amylin could trigger endoplasmic reticulum stress-induced apoptosis.[91] More recently, it 
was concluded that amylin oligomers could increase cytosolic levels of Ca2+ in the rat 
insulinoma cell line INS 832/13 which resulted in hyper activation of the protease calpein-2, 
leading to apoptosis.[92] 
 
The above mentioned mechanisms could possibly work together to eventually result in cell 
death. For example, membrane damage caused by the toxic species of amylin or ROS damage 
could potentially result in activation of the apoptotic pathway and previous studies have also 
shown that there is significant overlap of the different mechanisms responsible for amylin-
mediated cytotoxicity.[67, 93, 94] One such study used rat cortical neurons and demonstrated 
that amylin aggregates induced the apoptotic genes c-Jun, junB, c-fos and fosB as well as the 
oxidative stress genes cox-2 and lκB-α.[93] In addition, oligomers were found to contribute to 
membrane instability of voltage-clamped planar bilayer membranes by increasing 
conductance and electrical noise in the membrane as well as inducing the formation of 
abnormal vesicle-like membrane structures which resulted in apoptosis.[67] Gurlo et al. 
(2010) performed in vivo experiments with an oligomer-specific antibody and cryo-
immunogold labeling and showed that the toxic oligomer is present in the secretory pathway 
and is able to disrupt membranes therein as well as mitochondrial membranes.[94] These 
events results in cellular dysfunction and apoptosis.[94] Lim et al. (2010) further supported 
the hypothesis that the mechanism of amylin toxicity is membrane disruption by showing that 
mitochondrial proteins were deregulated when SH-SY5Y neuroblastoma cells were exposed 
to amylin.[95] However, this group also showed that production of ROS increased when cells 
were exposed to amylin.[95]  



























expression of the 
Fas ligand
AMYLIN INTERACTION WITH 
PLASMA MEMBRANE 




Figure 2.4 The proposed roles of the c-Jun, Fas and p53 proteins in apoptosis induced by 
human amylin in pancreatic beta cells. 
 
Taking into account all of the proposed and observed mechanisms of amylin-induced 
cytotoxicity, it thus appears that membrane disruption, generation of ROS and apoptosis are 
inter-related. Membrane disruption appears to have a direct effect on apoptosis and thus these 
two mechanisms could actually be working together to induce amylin-mediated cytotoxicity. 
 
2.4 Techniques used to monitor amylin aggregation and toxicity 
There are numerous techniques that are employed to monitor amylin aggregation and toxicity, 
and inhibition thereof. Two commonly used dyes for identification of the fibrillar form of 
amylin is Congo red and thioflavin T (ThT) (Figure 2.5). It was found that when bound to 
amyloid fibrils, Congo red produced a characteristic yellow-green birefringence under 
polarized light, and it was assumed that this dye interacted with the β-sheet structure that is 
present in all amyloid deposits.[96, 97] Thus, Congo red staining was initially used for 
classification purposes to ascertain if an aggregate is amyloidogenic in nature.[21, 96, 97]  
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Figure 2.5 Structures of Thioflavin T and Congo red. Adapted from Aitken et al. (2003).[98] 
 
Since Congo red staining is relatively easy to perform, it has been used to identify amyloid 
fibrils in pancreatic islets as well as in cell-based assays.[80, 96, 99] In addition, Congo red 
staining was used to identify the shortest fragment of amylin that retained amyloidogenic 
properties [36], to assess if modifications of the amylin structure could alter its amyloidogenic 
potential [61, 100], and to evaluate potential inhibitors of amylin fibril formation.[64] 
However, Congo red staining is neither very sensitive nor specific as it has been shown to 
stain amorphous aggregates [99] as well as having the ability to bind to cellular 
membranes.[101] Moreover, since Congo red is thought to bind β-sheet structures, it is quite 
possible that non-specific interactions could occur in a cell-based system, components of 
which may have β-sheet structures. It is also noteworthy that Congo red was found to reduce 
amyloid formation and affected the amyloidogenic properties of amylin [98, 102], thus 
precluding it as a suitable label for monitoring fibrillogenesis.  
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The other molecule used to detect amyloid fibrils is thioflavin T (ThT).[103] ThT is a thiazine 
dye that has a maximal excitation at 385 nm and emission at 445 nm. When attached to 
amyloid fibrils however, the maximum excitation is 450 nm and the emission is enhanced at 
485 nm.[103] The ThT assay is thus one of the most widespread assays used to detect the 
fibrillar species of amylin [69, 104] and also to screen molecules as potential inhibitors of 
amylin fibril formation.[60, 65, 74, 90, 98, 105, 106] However, to date, the exact mechanism 
of ThT binding to amyloid fibrils is yet to be determined. One hypothesis draws on the fact 
that ThT has both polar (the benzothiazole group containing nitrogen and sulphur) and 
hydrophobic (the dimethylamino group attached to a phenyl group) regions thereby allowing 
micelle formation in an aqueous environment.[107] The positively charged nitrogen pointing 
outside could then hydrogen bond to hydroxyl groups on amyloid fibrils, causing a change in 
excitation leading to enhanced fluorescence emission.[107] Although the ThT assay is very 
simple to perform, it does not yield quantitative data and could produce false positive results 
in the presence of amorphous aggregates.[99] Although Congo red and ThT can detect amylin 
aggregates, it does not indicate if these aggregates are the oligomeric or fibrillar species. 
 
To this end, microscopy techniques increased in popularity and transmission electron 
microscopy (TEM) became the technique of choice for visualizing amylin fibrils. Similar to 
the previous two techniques, TEM was used to identify the shortest fragment of amylin that 
formed typical amyloid fibrils [36, 47], to assess if modifications of the amylin sequence 
could alter its amyloidogenic potential [22, 61, 100], to follow amylin aggregation [68, 69, 
104], and hence to assess the potential of molecules as inhibitors of amylin fibril 
formation.[37, 60, 64, 65, 98, 106, 108] Although it is relatively easy to prepare the sample 
grids for TEM, image analysis requires a certain degree of skill and can be quite time-
consuming with each grid taking hours to be visually assessed. Since a very small volume of 
sample is used on each grid, fibrils can be missed leading to false negative results. However, 
scanning transmission electron microscopy (STEM) made a significant contribution to 
understanding the conformational changes during amylin agrgegation as it was the first 
technique used to determine the size of amylin aggregates that form.[45, 109] Some of the 
ground-breaking data garnered from STEM are that the amylin protofibril is 5 nm in width, 
higher order fibrils are formed by coiling of two protofibrils with a 25 nm axial cross-over 
repeat and are 8 nm in width, and that each 1 nm of protofibril length contains 2.6 human 
amylin molecules.[109] In addition, STEM-generated data were used in part to predict 
previously described models for β-sheet formation.[40, 41] 
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The other technique that allows visualization of amylin fibrils is atomic force microscopy 
(AFM). This technique was used to visualize fibril formation from full length amylin as well 
as a fragment of amylin that is homologous to the 20-29 region, and to size the aggregates that 
formed.[52, 110] One of the significant findings of AFM-based studies on amylin is that 
fibrils grow at a rate of 1.1 nm/minute and that the growth of the fibril is bidirectional.[52] 
The drawback to this technique is that it is not quantitative, it is labor-intensive, and samples 
must be adsorbed to a mica surface in order to monitor fibril growth over time. The latter 
drawback is a cause for concern since it has been reported that the type of amylin fibrils that 
form in the presence of a mica surface is significantly different in morphology from that 
formed free in solution.[52, 110] 
 
Since amylin aggregates adopt a β-sheet structure, techniques such as circular dichroism (CD) 
and Fourier transform infrared spectroscopy (FT-IR) that are able to give insight into the 
secondary structure of the peptide were extensively used. Circular dichroism (CD) is based on 
the concept that random coil structures have a maximum absorbance at 220 nm and minimum 
at 200 nm, the α-helix state absorbs maximally between 190-195 nm with a minimum 
absorbance between 208-222 nm, whilst β-sheets have a maximum absorbance between 195-
200 nm and a minimum between 215-220 nm.[37, 61] FT-IR spectroscopy is similar to CD in 
that it also uses differences in absorbance to identify the secondary structure of amylin.[13, 
35, 63, 98] A maximum absorbance at 1625-1630 cm-1 indicates the presence of β-sheets, 
whereas a maximum absorbance at 1660-1670 cm-1 reveals that a random coil structure is 
present.[13] These peaks are due to the stretching vibration of C=O and C-N groups and the 
shift to lower values is an indication of decreased hydrogen bonding interactions between 
these groups. 
 
Both CD and FT-IR spectroscopy techniques have been employed to determine the 
amyloidogenic region of amylin, the minimal sequence of amylin that retained fibrillogenic 
properties [36, 38, 39, 44, 47], and to monitor amylin aggregation and hence to elucidate the 
effect of potential inhibitors on the secondary structure of amylin.[13, 22, 37, 61, 64, 65, 68, 
100, 104, 105, 108, 111] Interestingly, CD was one of the earliest techniques used to 
determine that the oligomeric form of amylin is in a β-sheet conformation.[111] Although CD 
and FT-IR spectroscopy are easy to perform and can accurately determine the secondary 
structure of amylin, these techniques suffer a major drawback when used as a screening 
technique for potential inhibitors of amylin-induced cytotoxicity. This is due to the 
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observation that both the oligomeric and fibrillar forms of amylin are in a β-sheet 
conformation and thus these techniques cannot differentiate between these two species of 
amylin.[51, 111] Since it is widely accepted that the oligomeric form of amylin is cytotoxic 
whilst the fibrillar form is non-toxic [67-73], neither CD nor FT-IR spectroscopy can be 
exclusively used to screen inhibitors of amylin-mediated cytotoxicity.  
 
The sedimentation/precipitation assay is another technique that has been employed to 
determine the effect of peptides and other compounds on amylin fibril formation.[37, 98, 105] 
Initially this technique made use of the intrinsic fluorescence of tyrosine.[37] At specific time 
points, peptide samples are centrifuged and emission spectra of the supernatant are 
documented to determine the amount of amylin that has not precipitated and thus the amount 
of amylin that has aggregated can be ascertained.[37] An improved version of this assay made 
use of trace amounts of radio-labeled amylin, which are added to native amylin in the 
presence or absence of potential inhibitors.[98] After centrifugation, the amount of radio-
labeled amylin remaining in the supernatant is ascertained, hence allowing the amount of 
amylin that has been used for fibril formation to be calculated. Although this assay cannot 
differentiate between fibrils and oligomers, it has been used in conjunction with other assays 
to evaluate the potential of compounds as inhibitors of amylin-induced cytotoxicity. [37, 98, 
105] 
 
Thus, except for AFM, all previously mentioned techniques cannot solely identify amylin 
oligomers and since the oligomer is the toxic species [67-73], these techniques cannot be used 
to evaluate compounds as potential inhibitors of amylin-mediated cytotoxicity. 
 
The technique that clearly identifies the suitability of a compound as a potential therapeutic 
agent for type II diabetes is the cytotoxicity assay. This assay is conducted by exposing 
mammalian cells to amylin alone or mixtures of amylin and potential inhibitors, and 
evaluating cell viability after a set period of time. The following cell lines have been used for 
assessing inhibition of amylin-mediated cytotoxicity, PC12 (rat phaeochromocytoma cells), 
HIT-T5 (Syrian Hamster beta cells), HTB-14 (human glioblastoma/astrocytoma cells) and 
RIN-5F (rat pancreatic beta cells).[22, 36, 37, 60-62, 64, 65, 87, 88, 98, 105, 108, 112] To 
date, the RIN-5F cell line is the most commonly utilized for testing inhibitors of amylin-
mediated toxicity possibly due to the fact that it is a pancreatic beta cell line and hence the 
target of amylin-mediated cytotoxicity as would occur in an in vivo system. 
Chapter 2  Literature Review 
 
23 
The terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) [71, 
72, 91, 113], alamar blue [37, 112, 113], caspase [90], and (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide (MTT) [22, 36, 62, 64, 71, 105, 108] assays have been used to 
assess cytotoxicity, with the TUNEL and caspase assays detecting apoptosis specifically.  
 
The MTT assay is however, the most favored and relies on the fact that mitochondrial 
dehydrogenase that is present in actively metabolizing cells is able to cleave the tetrazolium 
salt 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) to yield purple 
formazan crystals. These crystals are thereafter solubilized and spectrophotometrically 
analyzed to yield quantitative data with respect to cell viability as the amount of purple 
crystals formed is directly proportional to the amount of viable cells present.[114] An 
improvement on the MTT assay is the MTS assay which involves a single-step protocol with 
the formazan product readily dissolving in cell culture medium thus reducing the assay 
time.[115] Although the MTT and MTS assay gives quantitative data with regard to the 
protective function of compounds, it is very expensive and time-consuming as it is dependent 
on the growth rate of a particular cell line. 
 
To the best of our knowledge, the only other cell-based technique for monitoring inhibition of 
amylin-mediated cytotoxicity makes use of fluorescence microscopy. This technique involves 
use of fluorescent-labeled amylin (Bodipy-amylin) and a fluorescent cellular membrane 
marker (Texas Red-DHPE), and cell imaging using a confocal microscope.[101] Once cells 
are exposed to amylin and the test compound, this technique allows detection of any changes 
in cell morphology that would indicate cell death. One of the most defining features of 
amylin-mediated cytotoxicity is the loss of cellular membrane integrity and this can be easily 
visualized using fluorescent-labeled amylin and a fluorescent cell membrane marker. 
Although this type of investigation gives excellent qualitative data, it has a few drawbacks. As 
with the cytotoxicity assay discussed earlier, this technique requires growth of mammalian 
cell lines which is both expensive and time-consuming. It is also critical to ensure that the 
fluorescent label does not interfere with the aggregation kinetics and toxic properties of 
amylin. It is therefore not feasible to use fluorescence microscopy as a screening technique for 
inhibitors of amylin-mediated toxicity. 
 
Seeing as cell-based systems can be quite time-consuming and labor intensive, and that no 
cell-free technique can be used exclusively to detect the oligomeric form of amylin, it is quite 
evident that a breakthrough is needed in development of a technique that would allow 
efficient screening of potential inhibitors of amylin-mediated cytotoxicity. 
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2.5 Inhibitors of amylin-mediated cytotoxicity 
The intitial strategy to design inhibitors of amylin-mediated cytotoxicity was based on the 
hypothesis that generation of ROS is the mechanism of toxicity. To circumvent the toxic 
effect of amylin-generated ROS, a number of quinone derivatives that were known to 
scavenge free radicals were evaluated.[60] However, it was found that only rifampicin and its 
analogs p-benzoquinone and hydroquinone inhibited the toxic effect of amylin whereas other 
anti-oxidants with scavenging ability did not exhibit any inhibitory effect on amylin 
toxicity.[60] This study was the first to observe that an inhibitor (rifampicin) could bind to 
amylin aggregates and prevent its attachment to the cell surface.[60] It was thus suggested 
that rifampicin and its analogs could have a dual mechanism to exert their protective function, 
preventing amylin-cell interaction and also scavenging ROS.[60] The thiol anti-oxidants N-
acetyl-L-cysteine, dithiothreitol, and the reduced form of glutathione were also found to 
significantly decrease amylin-mediated apoptosis whereas the free radical scavengers catalase 
and n-propyl gallate did not.[116] These results suggested that a protective function can be 
achieved by inhibiting the signalling pathways that are regulated by the redox state of thiol-
containing molecules as these could be responsible for amylin-induced cytotoxicity.[116]  
 
Thus, although amylin-mediated toxicity involves generation of ROS, as stated previously the 
toxic oligomeric species of amylin facilitates membrane disruption and could trigger a 
number of events that lead to apoptosis and cell death.[67, 94] To this end a significant 
amount of research focused on the core problem, inhibiting formation of the toxic species of 
amylin. 
 
Based on the finding that heteroaromatic interactions between amylin and polycyclic 
compounds resulted in geometric constraints that reduced fibrillogenesis, Aitken et al. (2003) 
highlighted the potential of polycyclic compounds as inhibitors of amylin-mediated 
cytotoxicity by reporting that Congo red, acridine orange and tetracycline could reduce 
amylin fibrillogenesis (Figure 2.6).[98] However, cytotoxicity testing was only performed 
with Congo red as it had no intrinsic toxicity and two separate studies found that Congo red 
reduced amyloid formation and ROS production, subsequently decreasing beta cell 
apoptosis.[98, 102] Another polycyclic compound, phenol red (Figure 2.6), was also found to 
reduce amylin-mediated cytotoxicity on beta cells, once again highlighting the role that 
heteroaromatic interactions have in inhibiting formation of amylin fibrils.[108] 
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Figure 2.6 Structures of acridine orange, tetracycline and phenol red. Adapted from Aitken et 
al. (2003) and Gazit (2005).[98, 117] 
 
The polyphenolic compound resveratrol that is found in grapes and red wine was also shown 
to significantly inhibit amylin fibril formation and the associated cytotoxicity [118]. Based on 
replica-exchange molecular-dynamics simulations, it was proposed that resveratrol reduces 
fibrillogenesis by preventing lateral growth of the amylin β-sheet.[119] A recent review 
indicated that even though resveratrol could have an impact on diabetes by a multitude of 
mechanisms as observed from in vitro testing, few clinical human trials have been conducted 
possibly due to its poor bioavailability.[120] To date, there is only one peer-reviewed human 
clinical trial that monitored the effect of resveratrol on insulin sensitivity in type II 
diabetes.[121] Although it was found that resveratrol does improve insulin sensitivity and 
reduces ROS [121], its effect on amyloid formation or inhibition of amylin-mediated 
cytotoxicity is yet to be monitored in an in vivo system. 
 
Interestingly, the only study that has performed in vivo testing to evaluate the effect of a 
known anti-amyloidogenic agent on diabetes was performed by Aitken et al. (2010).[73, 122] 
This study made use of transgenic mice and demonstrated that tetracycline (Figure 2.6) could 
delay onset and progression of diabetes.[73] However, to truly probe whether tetracycline acts 
by inhibiting amyloid formation, histopathological analysis would have been necessary and it 
is unfortunate that this type of examination was not performed. 
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Extending the search for molecules that could prevent amylin agggregation and its subsequent 
cytotoxicity, attention turned to peptides since it has low toxicity, high specificity and thus 
could be a viable option as a therapeutic agent. Since analysis of the rat amylin sequence 
implied that the unique presence of proline residues could be responsible for the lack of 
amyloid formation in rodents, the design of an inhibitor containing a proline substitution was 
encouraged. With this in mind, Abedini et al. (2007) synthesized full length amylin but 
substituted the serine at position 26 with proline and found that this modified peptide could 
bind to amylin and prevent fibril formation.[123] A possible explanation for this observation 
is that proline is known to induce β-turns in peptides, and since fibril growth requires a β-
sheet conformation of incoming amylin chains, a modified bent peptide will therefore disrupt 
the free stacking of β-sheet amylin molecules.[124]. Although this modified form of amylin 
inhibited amylin-mediated cytotoxicity, another amylin derivative that contains three 
substitutions with proline at residues 25, 28 and 29 was already undergoing clinical 
trials.[125-138] This amylin derivative was found to reduce blood glucose levels by 
decreasing glucagon secretion. This derivative was initially named symlin and thereafter 
marketed as pramlintide, and is currently used as an adjunct to insulin in the management of 
type II diabetes.[125-138] However, it should be noted that this peptide has not been 
evaluated as an inhibitor of amylin aggregation or amylin-mediated cytotoxicity.  
 
However, two other therapeutic agents of diabetes, Metformin and Rosiglitazone, were 
evaluated in an in vivo system to determine their effect on amyloid formation.[139] One of the 
therapeutic functions of Metformin and Rosiglitazone is to increase insulin sensitivity and 
hence reduce secretion of insulin from pancreatic beta cells.[139] In this study, transgenic 
mice that express amylin were treated with either Metformin or Rosiglitazone for twelve 
months and subsequent histopathological analysis revealed that these therapeutic agents 
significantly reduced the amount of amyloid deposits that formed in the pancreata of the 
treated animals.[139] As previously mentioned, amylin is secreted together with insulin from 
pancreatic beta cells and thus it was suggested that both Metformin and Rosiglitazone could 
possibly reduce amyloid formation by decreasing the amount of amylin secreted.[23, 139] 
This study thus highlights the need for developing molecules that could either prevent amylin 
secretion or reduce amyloid formation from amylin. 
 
Since full length amylin is difficult to chemically synthesize, attention shifted to shorter 
peptide sequences as potential inhibitors of amylin aggregation and subsequent amylin-
mediated cytotoxicity. A breakthrough was made whem Rijkers and coworkers (2002) found 
that the introduction of N-alkylated amino acids or ester functionalities into peptide sequences 
allowed the peptides to behave as β-sheet inhibitors that prevented the formation of toxic 
amylin β-sheets.[140]  
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As depicted in Figure 2.7A, single amylin strands form β-sheets by hydrogen bonding 
between N-H and CO dipoles that point outward from the amylin backbone. However, 
peptides containing N-alkylated amino acids and which exhibit a β-sheet conformation are 
able to bind to native amylin and prevent attachment of any further peptide strands by 
disrupting the hydrogen-bonding capacity of the peptide and by causing steric hindrance 
(Figure 2.7B).  
 
The presence of N-methylated (N-Me) amino acids improves the biostability of the peptide by 
being resistant to proteolysis and it also increases the membrane permeablity of the 
peptide.[141] Employing this approach, numerous amylin derivatives that incorporated N-
methylated amino acids were synthesized as potential inhibitors of fibril formation. The first 
of these inhibitors having the sequence SNNF(N-Me)GA(N-Me)ILSS was reported by 
Kapurniotu et al. in 2002.[64] This amylin derivative was shown to inhibit aggregation of the 
20-29 region of amylin, and prevented its cytotoxicity.[64] It was also found that the presence 
of N-methylations allowed the peptide to exist in an ordered β-sheet structure which is of 
importance since a stable conformation is crucial if the peptide is to be used as an 
inhibitor.[64] However, it should be noted that the effects of this amylin derivative was not 
assessed using full length amylin. The amylin derivatives that were evaluated as potential 
inhibitors of cytotoxicity caused by full-length human amylin are presented in Table 2.2. 
 





Figure 2.7 Illustration of how (A) unmodified amino acids can form β-sheet structures via 
hydrogen bonding (represented as ---) and how (B) N-methylations (expressed as dark circles) 
replaces hydrogen in a polypeptide and thus prevent β-sheet stacking. R1 – R4 represent the 
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Cell line used Reference 
Amylin20-25  25% RIN-1056A [37] 
Amylin24-29  0% RIN-1056A [37] 
Amylin12-17  0% RIN-1056A [112] 
Amylin15-20  0% RIN-1056A [112] 
Amylin22-27
 23 and 25 20% RIN 5fm [65] 
Amylin1-37 24 and 26 50% RIN 5fm [105] 
Amylin13-18  50% RIN-1056A [111] 
Amylin20-25  50% RIN-1056A [111] 
Amylin3-6  45% RIN 5fm [142] 
Amylin3-6
 3-5 0% RIN 5fm [142] 
Amylin9-13  40% RIN 5fm [142] 
Amylin9-13
 9, 12 and 13 0% RIN 5fm [142] 
Amylin15-20
  20% RIN 5fm [142] 
Amylin15-20
 15-17 and 19 0% RIN 5fm [142] 
Amylin22-27
  40% RIN 5fm [142] 
Amylin22-27
 23-27 0% RIN 5fm [142] 
Amylin29-34
  50% RIN 5fm [142] 
Amylin29-34
 30, 32-34 50% RIN 5fm [142] 
 
To the best of our knowledge, no in vivo testing was performed using any of the peptide 
inhibitors mentioned above. It is however noteworthy that two patents have been granted for 
peptide derivatives of amylin that can prevent amylin aggregation and amylin-mediated 
cytotoxicity, and which have been suggested as potential therapeutic agents of type II 
diabetes.[143, 144] However, the first patent was granted in 1996 whilst the second was 
granted in 2007 and to date, none of the derivatives mentioned have been used in clinical 
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In addition to peptide derivatives of amylin, a diverse range of other molecules were more 
recently assessed as potential inhibitors of amylin aggregation and cytotoxicity. The 
membrane binding protein annexin A5 was shown to decrease the toxic effect of amylin on 
rat pancreatic β-cells by 90%.[106] Cabaleiro-Lago et al. (2009) showed that N-
isopropylacrylamide:N-tert-butylacrylamide (NiPAM:BAM) co-polymeric nanoparticles were 
able to decrease amylin aggregation.[145] They suggested that amylin could possibly be 
adsorbed onto the nanoparticle surface thereby decreasing the available amount in solution 
and thus increasing the lag time of fibrillation.[145] It was also found that the sulfonated 
triphenyl methane derivative, acid fuchsin, decreased amylin-mediated toxicity by 
approximately 80%.[146] Rigacci et al. (2010) showed that oleuropein aglycon, the main 
phenolic component of extra virgin olive oil, reduced the toxicity of amylin by approximately 
20%.[147] However, these molecules need to be scrutinized further to ascertain its biostability 
and more importantly whether it is biodegradable. It is noteworthy that the toxicity of 
nanoparticles have been reviewed twice with the conclusion being drawn that nanoparticles 
are not easily cleared from an in vivo system and thus could lead to toxicity.[148, 149] 
 
2.6 Amylin synthesis 
At an early stage, it was found that amyloidogenic peptides from different suppliers have 
diverse properties [150], which was substantiated by a more recent study, that demonstrated 
the presence of impurities in commercially available amylin[151] It was also reported that the 
presence of impurities can affect the aggregation kinetics of amyloidogenic peptides [100, 
152, 153], thus highlighting the need for synthetic strategies that yielded pure protein. To this 
end, Raleigh et al. (2005) published the first synthetic strategy for amylin.[154] They made 
use of pseudoproline derivatives and to date there have been numerous improvements to their 
method.[104, 155-158] It is therefore deemed critical that a more cost effective and efficient 




It is thus quite evident that there exists a gap in respect to novel techniques that could enable 
fast and cheap screening of potential therapeutic agents for type II diabetes. That being said, 
although much progress has been made in respect to the type of inhibitor that could be used, 
peptide derivatives that could inhibit amylin-induced cytotoxicity could be developed further 
in a bid to find a potential therapeutic agent for type II diabetes. Most importantly, to gain 
more insight into amylin aggregation dynamics and also to screen potential inhibitors of 
amylin-mediated cytotoxicity, a cost effective strategy to acquire sufficiently pure amylin is 
deemed critical. 
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3.1 Abstract 
The 37-amino acid polypeptide amylin, is found as amyloid aggregates in the islets of 
Langerhans in patients with type II diabetes. Herein, we report an efficient microwave 
assisted solid phase peptide synthesis of amylin. The most efficient synthesis used double and 
triple couplings and 10 equivalents of amino acids. Double couplings were used for most 
amino acids, whereas triple couplings were utilized for amino acids in selected regions. The 
most effective method for formation of the disulfide bond in amylin was found to be iodine 
oxidation. Amylin with the highest purity was obtained when the crude peptide was purified 
with high performance liquid chromatography (HPLC) before formation of the disulfide bond. 
The cytotoxicity of the synthesized amylin product to RIN-5F cells was determined and it was 
found that the chemically synthesized amylin exhibits an exponential increase of cytotoxicity 
at concentrations >35 μM. Transmission electron microscopy studies illustrated that 
chemically synthesized amylin spontaneously formed insoluble typical amyloid fibrils after an 
incubation time of 24 hours in a suitable buffer. Thus, chemically synthesized amylin is 
suitable to use for screening potential inhibitors of fibril formation and cytotoxicity. 




Islet amyloid polypeptide (IAPP), also referred to as amylin, is a 37-amino acid polypeptide 
that is secreted by pancreatic β-cells together with insulin.[1] It is found in the pancreas, 
blood plasma, and gastrointestinal tract. Although little is known about the exact function of 
amylin in the human body, its soluble form is believed to play a role in glucose 
homeostasis.[1-5] 
 
From as early as 1901, a link between the deposition of fibrillar material in the islets of 
Langerhans in the pancreas and manifestation of type II diabetes had been established.[6] 
Because these deposits consisted mainly of amylin aggregated into fibrils, type II diabetes 
was classified as an amyloid disease.[6-8]  
 
Relatively large quantities of amylin are required to study the mechanism of aggregation or to 
screen for potential inhibitors of toxicity. However, the peptide is extremely expensive to 
purchase, and in our opinion, the quality varies greatly between suppliers possibly due to the 
difficulties associated with its synthesis and its tendency to form fibrils once synthesized and 
purified. Of note, a previous study reported that amyloidogenic peptides from different 
suppliers have diverse properties.[9] The highly hydrophobic sequence, which is the cause of 
its rapid aggregation, and the presence of a disulfide bridge between residues 2 and 7 are the 
factors that have made amylin difficult to synthesize efficiently.  
 
Raleigh and Abedini (2005) were the first to describe the use of pseudoproline derivatives for 
the solid phase peptide synthesis (SPPS) of amylin.[10] Raleigh et al. (2006) thereafter 
reported an improvement to the synthesis with air oxidation in dimethylsulfoxide (DMSO) or 
1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) to form the Cys-2 to Cys-7 disulfide bond.[10] The 
use of the solvent DMSO was reported as more efficient with a reaction time of just five 
hours as opposed to HFIP which required 24 hours.[11] They obtained an overall yield of 25–
28% based on the weight of the oxidized pure product compared with the weight of the crude 
material.[11] Park et al. (2008) also reported on the efficiency of using pseudoproline 
derivatives in synthesizing the linear peptide but described the formation of the disulfide 
bridge before cleavage of the peptide from the resin.[12] It was also reported that 1H-
benzotriazolium 1-[bis(dimethylamino) methylene]-5-chloro-hexa-fluorophosphate [1-], 3-
oxide (HCTU) is a superior coupling reagent if amylin is to be synthesized with faster 
coupling times using pseudoproline derivatives.[13] Kelly et al. (2008) improved the method 
of Raleigh and Abedini (2005) by successfully using single coupling of the pseudoproline 
derivatives and achieved a yield of 20 mg from a 0.1 mmol scale reaction.[10, 14] Although 
these methods are successful, they are not cost effective because pseudoproline derivatives are 
expensive to purchase or synthesize.  
Chapter 3  Research Results I 
 
42 
The recent introduction of microwave assisted SPPS has revolutionized this field. It has been 
reported to not only increase coupling efficiency but also to overcome near impossible 
coupling steps.[15-19] The use of 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU) or HCTU with temperatures of up to 95°C (via microwave 
SPPS) was shown to be beneficial for the synthesis of peptides that were previously reported 
as difficult with conventional methods.[18, 19]  
 
In addition, the introduction of ChemMatrix (CM) [20] resin, a total polyethyleneglycol 
(PEG) based resin comprised of primary ether bonds, has been reported to minimize some of 
the aggregation problems associated with polystyrene resins during the synthesis.[21-23] This 
resin swells efficiently in all of the common solvents and is therefore useful for a broad range 
of organic chemistries. CM resin performs extremely well compared with polystyrene resins 
in the solid-phase synthesis of hydrophobic, highly structured peptides such as poly-Arg 
peptide and β-amyloid(1–42) [21-23], showing that the presence of PEG chains impair the 
aggregation of the growing peptide chain, thereby facilitating the solid-phase synthesis of 
complex peptides. Thus, CM resins have been reported as the resin of choice for synthesis of 
hydrophobic peptides.[21, 22, 24]  
 
This communication describes for the first time the synthesis of amylin with the use of 
microwave assisted SPPS, using a CM resin, and without the use of pseudoproline 
derivatives. We also compared the reported efficiency of DMSO and/or HFIP for air 
oxidation and formation of the disulfide bridge, to that of oxidation with iodine. In a manner 
that mimics the biological activity of naturally occurring amylin, the newly synthesized 
amylin was also observed to form typical amyloid fibrils and was found to be cytotoxic to the 
RIN-5F cell line. 
 
3.3 Materials and Methods  
3.3.1 Reagents 
All 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids and coupling reagents were 
purchased from GLS Biochem Systems, Inc. (China). The following protecting groups were 
used for the side chains of the amino acids: trityl (Trt) for asn, cys, gln, and his, t-butyl ether 
(tBu) for ser and thr, 2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl (Pbf) for arg, and t-
butyloxycarbonyl (Boc) for lys. The Wang-CM resin was kindly donated by Matrix 
Innovation (Quebec, Canada). All solvents for synthesis and purification were of high 
performance liquid chromatography (HPLC) grade and were purchased from Sigma-Aldrich 
(U.S.A.). The CellTiter 96® nonradioactive cell proliferation assay was purchased from 
Promega Corporation (U.S.A.). 
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3.3.2 Linear peptide synthesis 
Peptides were synthesized on a 0.1 mmol scale using a CEM microwave peptide synthesizer. 
Deprotection was performed using 20% piperidine/DMF (v/v). Coupling was performed using 
1:1:1 amino acid/HBTU/N, N-diisopropyl ethylamine (DIPEA) in dimethylformamide 
(DMF). Three different synthetic strategies were tested. Strategy A made use of five molar 
equivalents (eq.) of all amino acids and double couplings for each, strategy B used ten molar 
equivalents of amino acids that proved to be problematic during synthesis and again double 
couplings, whereas strategy C used ten molar equivalents for the problematic amino acids and 
triple couplings for these. DMF top and bottom washes were performed between deprotection 
and coupling steps. The standard microwave settings from the manufacturer were modified 
according to Table 3.1. This method now includes 900 seconds of coupling without 
microwave heating in order to reduce racemization associated with excessive heating. 
 








Double coupling    
30 minute coupling 0 73 900 
35 73 900 
6 minute coupling 35 90 360 
Triple coupling    
30 minute coupling 0 73 900 
35 73 900 
6 minute coupling* 35 90 360 
Arginine coupling    
60 minute coupling* 0 73 2700 
35 73 900 
Deprotection 40 73 180 
* Double couplings.  
 
3.3.3 Cleavage 
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3.3.4 Oxidation to form the cys-2 to cys-7 disulfide bridge 
Methods 1 and 2 used air oxidation in DMSO and HFIP, respectively, as described by Raleigh et al. 
(2006) to form the disulfide bridge.[11] Briefly, method 1 involved dissolving crude amylin ( 20 mg) 
in 100% DMSO (10 mL) and subjecting it to air oxidation (five hours), whereas method 2 involved 
dissolving crude amylin ( 20 mg) in HFIP (10 mL) and 12 mL of 50 mM Tris buffer (pH 8.5), 
followed by air oxidation (24 hours). For method 3, crude amylin ( 20 mg) was dissolved in a large 
volume of methanol (400 mL). Iodine dissolved in methanol (10 mL) was then added drop-wise with 
continuous stirring until a faint yellow color was observed. The solvent was then evaporated and the 
crude product dissolved in DMSO before purification. This method was also applied to purified 
unoxidized amylin (16 mg), by dissolving it in an excess of methanol (400 mL) and adding methanolic 
iodine drop-wise (over 20 minutes) until a faint yellow color developed. The solvents were evaporated 
under reduced pressure at 40C and residual iodine was removed by azeotropic distillation with 
methanol. This amylin sample was lyophilized without further purification. 
 
3.3.5 Purification of unoxidized and oxidized amylin 
The unoxidized and oxidized amylin were purified directly via an ACE C18 preparative 
column (250 mm x 22 mm, Scotland). A dual-buffer system was employed, with TFA serving 
as the ion-pairing agent. The first buffer consisted of 0.1% TFA/H2O (v/v) and the second 
buffer was composed of 0.1% TFA/acetonitrile (v/v). The peptides were eluted using a 
gradient of 0-90% of the second buffer over 60 minutes with a flow rate of 20 mL/minute. 
The solvent from pooled peptide-containing fractions was evaporated to 20 mL and the 
samples were snap-frozen in liquid nitrogen and lyophilized. 
 
3.3.6 Peptide analysis 
Peptides were analyzed with an Agilent 1100 HPLC system fitted with a Waters XBridge C18 
column, 250  3.6 mm. Chromatography was performed over 90 minutes using a gradient of 
0-90% of 0.1% TFA/acetonitrile (v/v) at a flow rate of 0.3 mL/minute and the eluent was 
monitored at a UV wavelength of 215 nm. A Bruker electrospray ionization time-of-flight 
spectroscope (ESI-QTOF) in positive mode was used to obtain mass spectra (MS) and matrix 
assisted laser desorption ionization time-of-flight mass spectroscopy (MALDI-TOF MS) was 
performed with an Autoflex III instrument (Bruker) operated in positive mode with cyano-4-
hydroxycinnamic acid being used as the matrix. 
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3.3.7 Disaggregation method 
Before any testing could be performed, it was essential to start with completely disaggregated 
amylin. Although previous studies have recommended the use of either DMSO or HFIP alone 
for the purpose of amylin disaggregation [25-28], in the current study the following optimal 
procedure was established using transmission electron microscopy (TEM) studies. Amylin 
was dissolved in 200 µL hexafluoroisopropanol (HFIP):TFA solution (50:50, v/v) and the 
sample was sonicated for 10 minutes. Samples were then left to stand overnight at room 
temperature and the solvents removed under vacuum using a centrifugal evaporator for 
approximately 1-2 hours. Approximately 100 µL HFIP was added to the amylin, followed by 
vortexing and the solvent was removed by rotary evaporation for 1-2 hours. To remove all 
traces of TFA, the latter process was repeated twice using HFIP (100 µL). 
 
3.3.8 Transmission electron microscopy (TEM) 
Amylin was disaggregated as described earlier, and thereafter, dissolved in 10 mM sodium 
phosphate buffer, pH 7.4 containing 50 mM NaCl (Buffer A) to give a final concentration of 
45 μM. Aggregation was followed by TEM immediately following preparation as well as 
after 24 hours of incubation at 37°C. At each time-point, aliquots (2 μL) of the sample were 
applied onto formvar coated carbon-stabilized grids. After drying for one minute, excess 
liquid was blot dried and samples were stained with 2% (w/v) uranyl acetate for 30 seconds. 
Samples were blot dried again before being analyzed with a CM120 Biotwin Philips TEM at a 
voltage of 100 V. 
 
3.3.9 Cytotoxicity assay 
The RIN-5F cell line (European Collection of Cell Cultures, Sigma-Aldrich, U.S.A.) was 
cultured in RPMI 1640 growth medium containing 10% heat-inactivated fetal bovine serum, 2 
mM glutamine, 1 mM sodium pyruvate, 25 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl] 
ethanesulfonic acid (HEPES), and 0.1 mg/mL penicillin/streptomycin. Cells were plated at a 
density of 7.5 x 105 cells/mL (100 μL/well) into poly-D-lysine pre-coated 96 well plates 
(Sigma-Aldrich, U.S.A.) and incubated at 37C for 24 hours. 
 
Thereafter, spent medium was removed from all wells and fresh fully constituted medium was 
added (60 μL). Serial dilutions of amylin were prepared initially in 100 μL of Buffer A to 
which an equal volume of RPMI 1640 was then added. Thereafter, 40 μL samples containing 
varying concentrations of amylin were added to each well. Untreated control cells received 40 
Chapter 3  Research Results I 
 
46 
μL amylin-free samples that were disaggregated as described earlier and that were 
reconstituted in a solution containing equal volumes of Buffer A and RPMI 1640. 
Subsequently, plates were incubated at 37C for a further 24 hours. The CellTiter 96® 
nonradioactive cell proliferation assay was used as per manufacturer’s instructions to assess 
cell viability by measuring the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT).[29, 30] Absorbance readings for the MTT assay were 
performed using an Automated Microplate Reader (ELx800) from Bio-Tek Instruments. All 
assays were performed in quintuplicate and repeated twice. Statistical analysis was performed 
using the One-way Analysis of Variance (ANOVA) and Tukey-Kramer Multiple comparisons 
test (GraphPad InStat version 3 for Windows XP, U.S.A), and results were considered 
significantly different if p values were less than 0.05. 
 
3.4 Results 
Initially, amylin fragments 26–37, 18–37, 9–37, and then 2–37 were synthesized with double 
coupling of each amino acid. The major deletion products that contributed to the inefficient 
synthesis and purification were identified and are illustrated in Figure 3.1. Synthesis of the 
26–37 region of amylin was successful without any deletion products. However, when the 
18–37 region was synthesized, it was found that several amino acids in the 18–23 region were 
missing. Subsequent synthesis of the 9–37 and 2–37 regions identified difficult coupling 
sequences with amino acids in the 11–14 and 3–6 segments. The identified difficult sequences 
were in accordance with predictions from the peptide companion software.[31] 
(i) I L S S T N V G S N T Y
2 10 20 30 37
(ii) H S S N N F G A I L S S T N V G S N T Y
(iii) T Q R L A N F L V H S S N N F G A I L S S T N V G S N T Y
(iv) C N T A T C A T Q R L A N F L V H S S N N F G A I L S S T N V G S N T Y
 
Figure 3.1 Sequence of amylin fragments homologous to the 26-37 (i), 18-37 (ii), 9-37 (iii), 
and 2-37 (iv) regions. Missing amino acids are underlined. 
 
Three different synthetic strategies were then used to synthesize full length amylin and the 
HPLC trace of each strategy can be observed in Figures 3.2 and 3.3. Strategy C (Figure 3.3) 
indicates that a more pure product is present than that achieved with either strategy A (Figure 
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3.2A) or strategy B (Figure 3.2B). In addition, the desired product from strategy C would 
elute independently during HPLC purification. 
Three different methods were then tested for the formation of the disulfide bridge between 
residues 2 and 7. The first two strategies involved air oxidation in DMSO and HFIP, 
respectively, as described by Raleigh et al. (2006).[11] However, air oxidation in DMSO only 
reached completion after five days, whereas the use of HFIP in Tris buffer resulted in 
formation of a precipitate and proved unsuccessful for formation of the disulfide bridge. A 
third method involved the use of iodine for oxidation. The reaction reached completion 
quickly (approimately 20 minutes) and the oxidized peptide was then purified. As illustrated 
in Figures 3.4, it is clear that this method still yields a large fraction of impurity. However, as 
seen in Figure 3.5, oxidation after purification results in presence of a pure peptide. The latter 
synthetic strategy resulted in a yield of 8% (32 mg), based on using a 0.1 mmol scale for 
synthesis. 
 
As determined by MALDI-TOF MS analysis (Figure 3.6), the molecular weight of 
commercially available amylin (m/z  3905.5) is comparable with that of chemically 
synthesized amylin (m/z  3905.4). Unlike chemically synthesized amylin, a substantial 
impurity (m/z  2926.0) was present in commercially supplied amylin (Figure 3.6B). The 
contaminants in both samples could be as a result of deletion products which are known to 
form during the chemical synthesis of amylin. 





























































Figure 3.2 Analytical reverse-phase HPLC traces of crude samples of amylin using different 
synthetic strategies: (A) double couplings and 5 eq. of all amino acids (strategy A); and (B) 
double couplings and 10 eq. of specific amino acids (strategy B). All HPLC traces were run at 
a gradient of 0-90% of 0.1% TFA in acetonitrile (v/v) over 90 minutes. # indicates the elution 
position of the desired product. 
 


































Figure 3.3 Analytical reverse-phase HPLC trace of crude samples of amylin using strategy C 
(triple couplings and 10 eq. of specific amino acids). All HPLC traces were run at a gradient 
of 0-90% of 0.1% TFA in acetonitrile (v/v) over 90 minutes. # indicates the elution position 




















Figure 3.4 Analytical reverse-phase HPLC traces of crude samples of amylin after iodine 
oxidation. HPLC traces were run at a gradient of 0-90% of 0.1% TFA in acetonitrile (v/v) 
over 90 minutes. # indicates the elution position of the desired product. 



































Figure 3.5 Analytical reverse-phase HPLC traces of (A) purified unoxidized amylin; and (B) 
amylin after oxidation using iodine. HPLC traces were run at a gradient of 0-90% of 0.1% 























































Figure 3.6 MALDI-TOF MS analysis of (A) chemically synthesized amylin and the best 
commercially available amylin (B). Arrows in (A) and (B) indicates the correct mass of 
amylin (m/z = 3905.4 and 3905.5 respectively). * indicates the impurity (m/z = 2926.0). 
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TEM was performed to determine the amyloidogenic nature of the chemically synthesized 
amylin and as observed in Figure 3.7, the synthesized amylin forms typical amyloid fibrils. 
Figure 3.8 illustrates a lag phase in cytotoxicity when 5–35 μM of amylin was used. 
Thereafter, an exponential increase in cytotoxicity was observed. 
 
 
Figure 3.7 Electron micrograph illustrating spontaneously formed amyloid fibrils in a 45 μM 
sample of chemically synthesized amylin after 24 hours of incubation in 10 mM sodium 
phosphate buffer, pH 7.4 containing 50 mM NaCl. Scale bar = 200 nm. 
 
 
Figure 3.8 The cytotoxic effect of various concentrations of amylin on RIN-5F cells (7.5  
104 cells/well after 24 hours incubation with amylin). Data are percentages of control, with 
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run 1 and run 2 being two independent experiments, each of which was performed with 
multiple replicates (n=5). When compared to the control, p values for 45 μM amylin were < 
0.001 for both runs. 
3.5 Discussion 
In the synthesis of amylin, strategy A made use of a five-fold excess of all amino acids with 
double couplings for each residue. Although the desired peptide was obtained (m/z  3905), 
large amounts of two deletion peptides (m/z  3438 and m/z  2595) were also present. 
Deletion peptide 1 (m/z  3438) was attributed to the absence of amino acids in the 18–23 
region, whereas the other major deletion peptide 2 (m/z  2595) was present due to inefficient 
coupling of residues in the 3–6, 11–14, and 18–23 regions. There are several other deletion 
products but they would not affect the purification of the desired peptide. Strategy B involved 
using five equivalents of each amino acid with double couplings, whereas ten equivalents 
were utilized for the 3–6, 11–14, and 18–23 regions. This approach proved to be a more 
successful strategy by significantly reducing the peak corresponding to deletion peptide 2. 
Deletion peptide 1 (m/z  3438) forms as a result of inefficient coupling of the two asn, phe 
and ser residues belonging to the 18–23 region. Relying on the findings of the first 2 
strategies, strategy C was then performed using a ten-fold excess of amino acids for the 
difficult regions as in strategy B but with triple couplings for amino acids in the 18–23 region. 
This approach proved more efficient in reducing the amount of deletion peptide 1 and the 
analytical HPLC profile indicated an easier isolation of the desired linear amylin. 
 
Of the three methods tested for the formation of the disulfide bridge between residues 2 and 7, 
iodine oxidation was the most successful when performed after purification of the unoxidized 
peptide since there was no need for purification after oxidation. The retention times of 
reduced and oxidized amylin differed by approximately two minutes, which is in agreement 
with previously reported data.[10] Using our best synthetic strategy, this study reported a 
yield of 32 mg on a 0.1 mmol scale which is similar to that obtained by Kelly et al. (2008) 
(yield of 20 mg).[14] However, in this study the pseudoproline derivatives were replaced with 
normal Fmoc amino acids and a 10 molar excess with triple couplings were used for the 
assigned difficult regions. This synthetic strategy is thus far cheaper than the strategy using 
pseudoprolines when prices for commercially available pseudoproline derivatives are taken 
into account. As indicated by MALDI-TOF MS, chemically synthesized amylin had a similar 
molecular weight as that of commercially available amylin. In addition, the chemically 
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synthesized amylin had a similar aggregating potential as both commercially available as well 
as naturally occurring amylin since it formed typical amyloid fibrils.[32-34] 
 
Considering the variations reported in both the concentrations of amylin used and the 
percentage cytotoxicity observed in previous studies, a range of amylin concentrations (5–45 
μM) were screened in this study. It seems from literature that commercial samples of isolated 
amylin lead to dramatic variations in toxicity toward the same cell line (RIN-5F). Bai et al. 
(1999) found that 5 μM amylin was 20% toxic [35] whilst subsequent studies reported a 20% 
toxicity arising from lower concentrations of amylin, 100 nM [31], 10 nM [27] and even 1 nM 
[28]. It was also reported that 280 nM amylin was approximately 8% toxic.[36] In the present 
study, an exponential increase in cytotoxicity of chemically synthesized amylin was observed 
which correlates with that observed in previously published studies that made use of 
commercially available amylin.[27, 28] Thus, the chemically synthesized amylin also exhibits 
a similar cytotoxic potential as that of commercially available amylin, thereby allowing it to 
be used to screen potential inhibitors of amylin-mediated aggregation and cytotoxicity. 
 
3.6 Conclusion 
Linear amylin can be efficiently synthesized without the use of pseudoproline derivatives. 
This is the first report of amylin synthesis by using microwave assisted SPPS with CM resin 
and it seems to generate fewer impurities in comparison with previously published strategies. 
Furthermore, we have shown that iodine is a fast, efficient, and facile method for disulfide 
bond formation. The oxidation process was proven to be successful on both impure and pure 
amylin product. We propose that this approach is a cost-effective improvement on the 
reported synthesis of amylin thus far. The cytotoxicity of pure amylin was determined on the 
RIN-5F cell line and it was shown that amylin concentrations of >35 µM exhibit an 
exponential increase in toxicity, making chemically synthesized amylin suitable for screening 
potential inhibitors of amylin-mediated cytotoxicity. 
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As the world moves towards a more Westernized diet, type II diabetes, a disease that 
debilitates by its many secondary complications, has been shown to be on the increase each 
year. Deposits consisting mainly of a small protein, called islet amyloid polypeptide (amylin), 
which aggregates into oligo-/polymeric β-sheet structures are responsible for toxicity to the 
pancreatic beta cells, thus leading to this disease. Hence inhibition of the aggregation process 
has been explored as a potential prevention or treatment of type II diabetes. N-methylated and 
non-methylated peptides spanning the length of amylin were synthesized and evaluated for 
their inhibition of full length amylin-mediated cytotoxicity to RIN-5F cells. The non-
methylated peptides were very effective in inhibiting the cytotoxicity of amylin while the N-
methylated peptides were not. Both the N-methylated and non N-methylated versions of the 
29-34 region of amylin were equally effective.  
 




The incidence of type II diabetes also referred to as non-insulin dependent diabetes mellitus is 
on the increase each year and the World Health Organization (WHO) predicts there to be over 
360 million diabetic patients worldwide by the year 2030.[1] From as early as 1901, a link 
between the deposition of fibrillar material in the Islets of Langerhans in the pancreas and 
manifestation of type II diabetes had been established.[2] It was found that the deposits 
consisted mainly of a small protein, called amylin, which aggregates into amyloid fibrils and 
type II diabetes was thus classified as an amyloid disease.[2-4] Amylin is a 37-amino acid 
long polypeptide and is released from the β-granules of pancreatic beta cells together with 
insulin in a constant molar ratio of 20:1 (insulin/amylin). It is believed to play a role in 
maintaining glucose homeostasis and was found to be released by the body following an 
increase in blood glucose levels, as is the case after a meal.[5, 6] Soluble monomeric amylin 
is stabilized when it self-associates via hydrogen bonding into β-sheet oligomeric states and 
can further associate into insoluble amyloid fibrils.[7, 8] The exact nature of the toxic species 
is controversial with some researchers arguing that amyloid fibers are toxic [9-17] whilst 
others have shown that the pre-amyloid intermediates (oligomers) exert the toxic effect.[18-
22] 
 
In 2002, it was found that the introduction of N-alkylated amino acids or ester functionalities 
into peptide sequences allowed the peptide to act as β-sheet inhibitors and prevented 
toxicity.[23] Single strands form β-sheets by hydrogen bonding between NH- and O moieties 
that point out of the peptide backbone. Peptides containing N-alkylated amino acids are able 
to bind to the native protein and prevent the attachment of any further peptide strands by 
disrupting the hydrogen-bonding capacity and by providing steric hindrance. In 1990, 
Westermark et al. found that the 20–29 region alone was able to form amyloid fibrils and for 
many years it was believed that this was the only region that was crucial for aggregation into 
cytotoxic fibrils.[24] This hypothesis was further supported when it was found that the 22–27 
region is the shortest fragment of amylin that could form the typical cytotoxic amyloid 
fibrils.[25] However, a later study demonstrated that the 8–20 fragment is capable of forming 
fibrils that have the β-sheet conformation.[26] More recently, Abedini and Raleigh (2006) 
synthesized the 8–37 region of amylin, substituting residues at positions 17, 19 and 30 for 
proline and showed that the modified peptide had a significant lack of aggregating potential as 
compared to its wild type peptide.[27]  
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The sequence SNNF(N-Me)GA(N-Me)ILSS was reported as one of the first peptide-based 
inhibitors that reduced toxicity of the 20–29 region of amylin.[15] It was also reported that the 
presence of N-methylated amino acids allowed the peptide to exist in an ordered β-sheet 
structure which was crucial if the peptide was to be used as an inhibitor.[15] However, to date 
only two other modified peptides were shown to inhibit the aggregation of full length amylin 
and its subsequent cytotoxicity. The first of these two peptides made use of the full length 
amylin with N-methylations in positions 24 and 26 and the second was a hexapeptide 
homologous to the 22–27 region with N-methylated amino acids in the 23 and 25 
positions.[16, 28]  
 
In addition, there is only a limited number of studies that describe the evaluation of 
unmodified amylin derivatives as inhibitors of full length amylin-mediated cytotoxicity. 
Scrocchi et al. (2002) focused on the 20–29 region of amylin and observed that amylin20–25 
reduced amylin-mediated toxicity by 25% whereas amylin24–29 did not.[29] However, it 
should be noted that amylin alone was only 35-40% toxic to RIN-1056 cells. In a later report, 
the 12-17 and 15-20 regions of amylin were tested as potential inhibitors of toxicity on the 
RIN-1056 cell line and it was reported that neither of the two peptides were successful.[30] 
Amylin13–18 was observed to completely prevent amylin-mediated cytotoxicity on RIN-1056A 
cells and when freshly cultured human islets were exposed to full length amylin, this 
derivative reduced the amount of apoptotic cells from 25% to 12.5%.[31] The 20-25 region of 
amylin was also observed to reduce amylin toxicity by 50%.[31]  
 
When working with amyloid proteins, it is difficult to compare results between reports. In this 
communication we thus report the synthesis of ten short N-methylated and non-methylated 
amylin derivatives spanning the full length of amylin and evaluated these via a cytotoxicity 
assay in a single study. It was also decided to use as many N-methylated amino acids in each 
peptide as synthetically possible since it was recently reported by Arvidsson et al. (2009) that 
a hexapeptide with five N-methylations was effective in inhibiting toxicity mediated by Aβ1–42 
protein.[32] Interestingly, the general trend observed was that the non-methylated peptides 
were better inhibitors of amylin-induced cytotoxicity than their N-methylated counterparts, 
with the exception of the N-methylated derivative of the 29-34 region of amylin which 
displayed an equal inhibitory effect as its non-methylated counterpart.  
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4.3 Materials and methods 
4.3.1 Reagents 
Rink amide resin, and all 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids and 
coupling reagents were purchased from GLS Biochem Systems, Inc. (China). The following 
protecting groups were used for the side chains of the amino acids: trityl (Trt) for asn, cys, 
gln, and his, t-butyl ether (tBu) for ser and thr, 2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-
sulfonyl (Pbf) for arg, and t-butyloxycarbonyl (Boc) for lys. The Wang-CM resin was kindly 
donated by Matrix Innovation (Quebec, Canada). All solvents for synthesis and purification 
were of high performance liquid chromatography (HPLC) grade and were purchased from 
Sigma-Aldrich (U.S.A.). The CellTiter 96® nonradioactive cell proliferation assay was 
purchased from Promega Corporation (U.S.A.). 
 
4.3.2 Peptide synthesis 
Human amylin (1–37) was synthesized as described in Chapter 3. Amino acids were N-
methylated as described by Zhang et al. (2005).[33] Synthetic peptides spanning the length of 
amylin (Figure 4.1) were synthesized on a CEM microwave peptide synthesizer using rink 
amide resin and standard Fmoc-based solid phase peptide synthesis methodology. 
Deprotection was performed using 20% piperidine in dimethyl formamide (DMF). The 
activator used in the synthesis was 0.5 M 2-(1H-benzotriazole-1-yl)-1, 1, 3, 3-
tetramethyluronium hexafluorophosphate (HBTU) in DMF, with 1 M N, N-
diisopropylethylamine (DIPEA) in DMF serving as the activator base. The peptides were 
cleaved from the resin using 5% tri-isopropylsilane in trifluoroacetic acid (TFA) (v/v) for one 
hour. They were then purified by reverse phase preparative HPLC on an ACE C18 
preparative column (250  22 mm, Scotland) using a dual-buffer system. The first buffer 
consisted of 0.1% trifluoroacetic acid (TFA) in water (v/v) whilst the second buffer was 
composed of 0.1% TFA/acetonitrile (v/v). The peptides were eluted using a gradient from 10-
60% acetonitrile over 45 minutes. The solvent from pooled peptide-containing fractions was 
evaporated and the samples were snap-frozen in liquid nitrogen and lyophilized. The purified 
peptides were analyzed with an Agilent 1100 HPLC system fitted with a Waters XBridge C18 
column, 250  3.6 mm. A Bruker electrospray ionization time-of-flight spectroscope (ESI-
QTOF) in positive mode was used to obtain mass spectra (MS) and matrix assisted laser 
desorption ionization time-of-flight mass spectroscopy (MALDI-TOF MS) was performed 
with an Autoflex III instrument (Bruker) operated in positive mode with cyano-4-
hydroxycinnamic acid being used as the matrix.  
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Figure 4.1 Primary structure of full length human amylin and the N-methylated and non-
methylated amylin derivatives that were synthesized as potential inhibitors. Single letter 
notation used for amino acids and N-methylated amino acids are underlined. m1-m5 and n1-
n5 are shorthand notations that are used to denote the N-methylated amylin derivatives and 
their non-methylated counterparts respectively. 
 
4.3.3 Circular dichroism spectroscopy (CD) 
CD measurements were carried out using a Jasco J-810 spectropolarimeter (c = 0.1 mmol, 
25C). Wavelength scans were performed with a minimum of five repeats. 
 
4.3.4 Disaggregation method 
Before any testing could be performed, it was essential to start with completely disaggregated 
amylin. As described in Chapter 3, disaggregation was achieved by solubilizing amylin in 200 
µL hexafluoroisopropanol (HFIP):TFA solution (50:50, v/v) and sonicating for 10 minutes. 
Samples were left overnight and solvents were then removed under vacuum using a 
centrifugal evaporator for approximately 1-2 hours. Thereafter, approximately 100 µL HFIP 
was added to the peptide, followed by vortexing and the solvent was removed by rotary 
evaporation for 1-2 hours. To remove all traces of TFA, the latter process was repeated twice 
using HFIP (100 µL). 
 
4.3.5 Transmission electron microscopy (TEM) 
To monitor fibril formation, amylin was disaggregated as described above and solubilized in 10 
mM sodium phosphate buffer, pH 7.4 containing 50 mM NaCl (Buffer A) by sonicating for five 
minutes to give a final concentration of 45 μM. TEM was performed as follows immediately 
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following preparation as well as after 24 hours of incubation at 37C. At each time point, 2 µl 
aliquots of sample were transferred onto formvar coated carbon-stabilized copper grids. After 
drying for one minute, excess liquid was blot dried and samples were stained with 2% (w/v) 
uranyl acetate for 30 seconds. Samples were blot dried again before being analyzed with a CM120 
Biotwin Philips transmission electron microscope at a voltage of 100 V. 
 
To evaluate the effect of each amylin derivative on amylin fibrillogenesis, each amylin derivative 
was added to lyophilized samples of disaggregated amylin to yield a final ratio of 50 μM:250 μM 
(amylin:amylin derivative). Mixtures of amylin and each of the amylin derivatives were sonicated 
for five minutes before TEM was performed as described above. 
 
4.3.6 Cytotoxicity assay 
The RIN-5F cell line (European Collection of Cell Cultures, Sigma-Aldrich) was cultured in 
RPMI 1640 growth medium containing 10% heat-inactivated fetal bovine serum, 2 mM 
glutamine, 1 mM sodium pyruvate, 25 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl] 
ethanesulfonic acid (HEPES), and 0.1 mg/mL penicillin/streptomycin. Cells were plated at a 
density of 7.5  105 cells/mL (100 μL/well) into poly-D-lysine precoated 96 well plates 
(Sigma-Aldrich) and incubated at 37 C for 24 hours. Thereafter, spent media were removed 
from all wells and fresh fully constituted media were added (60 μL). Samples containing 
disaggregated amylin only (45 μM), amylin derivatives only (50-1000 μM) or mixtures of 
disaggregated amylin (45 μM) and each of its derivatives (225 μM),  were prepared as 
described for TEM. Thereafter, 40 μL of each sample was added to each well whilst untreated 
control cells received 40 μL amylin-free samples that were disaggregated as described above 
and reconstituted in buffer solution. Plates were incubated at 37 C for a further 24 hours 
before the CellTiter 96® non-radioactive cell proliferation assay was performed. This assay 
was carried out as per manufacturer’s instructions to assess cell viability by measuring the 
cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT).[20, 22] Absorbance readings for the MTT assay were performed using an Automated 
Microplate Reader (ELx800) from Bio-Tek Instruments. Statistical analysis was performed 
using the One-way Analysis of Variance (ANOVA) and Tukey-Kramer Multiple comparisons 
test (GraphPad InStat version 3 for Windows XP, U.S.A) and results were considered 
significantly different if p values were less than 0.05. 




As illustrated in Table 4.1, all amylin derivatives were synthesized with a high yield and all 
peptides had a purity of >95%. 
 









NTAT (n1) 405.2 406.2 96 
TQRLA (n2) 587.6 588.2 88 
FLVHSS (n3) 688.4 689.2 90 
NFGAIL (n4) 633.4 634.4 93 
STNVGS (n5) 563.3 564.3 92 
NTAT (m1)* 488.5 489.3 93 
TQRLA (m2)* 629.4 630.2 70 
FLVHSS (m3)* 785.9 786.4 85 
NFGAIL (m4)* 744.8 745.4 88 
STNVGS (m5)* 660.7 661.3 90 
* N-methylated amino acids are underlined 
 
Circular dichroism (CD) spectroscopy measurements were taken of each peptide to determine 
its secondary structure. CD is based on the ability of optically active molecules ability 
preferentially absorbs either left- or right-handed circularly polarized light. The non-
methylated amylin derivatives appear to be primarily unstructured in solution since the entire 
spectra exhibit a minimum around 200 nm and lack significant intensity between 210 and 230 
nm (Figure 4.2). However, all of the amylin derivatives containing N-methylated amino acids 
displayed a β-sheet secondary structure since its maxima is at approximately 200 nm with a 
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Figure 4.2 CD spectra of the non-methylated amylin derivatives n1-n5 indicating that these 
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Figure 4.3 CD spectra of the N-methylated amylin derivatives m1-m5 indicating that these 
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Transmission electron microscopy was performed to determine the effect of each amylin 
derivative on amylin fibril formation. TEM of all samples immediately after preparation 
revealed that no fibrils were present. After an incubation time of 24 hours, typical amyloid 
fibrils was observed in the sample containing amylin only (Figure 4.4). TEM analysis of 
samples containing amylin and each of its derivatives illustrated that with the exception of n1 
and m5, all the other amylin derivatives (n2-n5 and m1-m4) did not prevent amylin 
aggregation into a typical fibrillar structure (Figures 4.5 and 4.6) after an incubation time of 
24 hours. Amylin derivatives n1 and m5 appears to delay fibril formation as very few 
amorphous aggregates (Figure 4.7) were observed after an incubation time of 24 hours.  
 
The cytotoxicity assay was performed to ascertain if any of the amylin derivatives were 
cytotoxic to the RIN-5F cell line and if they could reduce amylin-mediated cytotoxicity to 
these cells. The control studies indicated that the amylin derivatives were non-toxic to the 
RIN-5F cell line. As seen in Figure 4.8, amylin was approximately 70% toxic to RIN-5F cells. 
However, in the presence of the non-methylated amylin derivatives n1, n2, n4, and n5, the 
toxic effect of amylin was drastically reduced with p values less than 0.001. Amylin 
derivative n1 reduced the toxic effect of amylin from 70% to 25%, while derivatives n2 and 
n4 decreased toxicity by approximately 50%. Of the non-methylated amylin derivatives, n5 
seems to be the best inhibitor and resulted in a decrease in toxicity from 70% to 
approximately 18% whereas derivative n3 decreased toxicity by only 20% (p <0.01). It was 
found that the N-methylated peptide fragments m1–m4 did not reduce the toxic effect of 
amylin (p >0.05) while, m5 (which is homologous to amylin29–34 and contains four N-
methylated amino acids) proved to be just as effective as its non-methylated derivative and 
decreased cytotoxicity from 70% to just 18% (p <0.001). 
 
 





Figure 4.4 TEM analysis of samples containing amylin only after 24 hours incubation at 
37C in 10 mM sodium phosphate buffer, pH 7.4 containing 50 mM NaCl. Typical amyloid 
fibrils are observed in the electron micrograph of the sample containing amylin only. Scale 
bar = 200 nm. 
 










Figure 4.5 TEM analysis of samples containing a mixture of amylin and each of its 
derivatives after 24 hours incubation at 37C in 10 mM sodium phosphate buffer, pH 7.4 
containing 50 mM NaCl. Typical amyloid fibrils are observed in the electron micrographs of 
samples containing amylin its derivatives n2 (A), n3 (B), n4 (C), and n5 (D) respectively. 
Scale bar = 200 nm. 
 










Figure 4.6 TEM analysis of samples containing a mixture of amylin and each of its 
derivatives after 24 hours incubation at 37C in 10 mM sodium phosphate buffer, pH 7.4 
containing 50 mM NaCl. Typical amyloid fibrils are observed in the electron micrographs of 
samples containing amylin its derivatives m1 (A), m2 (B), m3 (C), and m4 (D) respectively. 
Scale bar = 200 nm. 
 





Figure 4.7 TEM analysis of samples containing a mixture of amylin and each of its 
derivatives after 24 hours incubation at 37C in 10 mM sodium phosphate buffer, pH 7.4 
containing 50 mM NaCl. Amorphous aggregates are present in samples containing amylin 
and derivatives n1 (A) and m5 (B) respectively. Scale bar = 200 nm. 
 
Figure 4.8 The cytotoxic effect of amylin (45 μM) on RIN-5F cells (7.5  104 cells/well after 
24 hours incubation with amylin) in the presence or absence of its derivatives (225 μM), as 
determined by the MTT assay. Data are percentages of control values and are the mean (SD) 
of five determinants. A = amylin, n1-n5 = non-methylated and m1-m5 = N-methylated 
derivatives of amylin. When compared to A, p < 0.001 for A+n1, A+n2, A+n4, A+n5 and 
A+m5; p<0.01 for A+n3; and p>0.05 for A+m1, A+m2, A+m3 and A+m4. 




As mentioned previously, derivatives of amylin have potential as inhibitors of amylin-
mediated cytotoxicity and hence could be developed into therapeutic agents for type II 
diabetes. This study thus aimed to synthesize tetra- and hexa-peptide amylin derivatives 
spanning the length of amylin to evaluate their effect on fibril formation and amylin-mediated 
cytotoxicity. Analogs of these amylin derivatives were also synthesized with some of its 
constituent amino acids being substituted by N-methylated amino acids to assess if the 
presence of methyl groups could improve the ability of each amylin derivative to inhibit 
fibrillogenesis and/or amylin-mediated cytotoxicity. 
 
As previously mentioned, the non-methylated amylin derivatives n2-n5 did not prevent 
fibrillogenesis. This observation is in agreement with other reports that have shown with the 
exception of amylin3-6, that all other non-methylated amylin derivatives (n2-n5) were 
constituents of the amyloidogenic region of amylin.[8, 24-26, 29, 30, 35-40] In addition, 
amylin derivatives n2-n5 each contain at least one of the proposed nucleation sites for amylin 
aggregation.[41] It is noteworthy that amylin derivative n1 appears to delay fibril formation 
which is supportive of the hypothesis that the 1-7 region of amylin is in a random coil 
conformation and could have a modulating effect on amylin aggregation, that is the 
amyloidogenic nature of amylin is increased if this region is excluded from the amylin 
sequence.[26] However, all of the non-methylated amylin derivatives significantly reduced 
amylin-mediated cytotoxicity. Thus, it could be suggested that the non-methylated amylin 
derivative n1 retards amylin aggregation into toxic aggregates whilst the derivatives n2-n5 
could potentially increase fibrillogenesis of amylin into non-toxic fibrils and thus our data 
supports the theory that the oligomer is the toxic species of amylin.[18-20, 22, 42-44] Of all 
the amylin derivatives analyzed in this study, only derivative n3 was previously evaluated as 
an inhibitor of amylin-mediated cytotoxicity.[30] Although it was found that this derivative 
did not reduce cytotoxicity, it should be noted that the previous study did not report on 
whether amylin was completely disaggregated prior to it being used in the cytotoxicity assay 
which could have a major impact on data generated.[30]  
 
Contrary to expectations, the N-methylated amylin derivatives m1–m4 did not reduce 
fibrillogenesis and neither did they inhibit the toxic effect of amylin. It can therefore be 
suggested that the introduction of N-methylated amino acids into peptides does not always 
result in inhibition of fibril formation, an observation that has previously been reported.[45] 
In addition, further testing is necessary to probe amylin-amylin aggregation and to determine 
why N-methylated peptides in general do not prevent fibril formation.  
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However, amylin derivative m5 (which is homologous to amylin29–34 and contains four N-
methylated amino acids) proved to be just as effective as its non-methylated analog and also 
resulted in a 60% reduction of amylin-mediated cytotoxicity. Since both versions of amylin29–
34 could significantly reduce toxicity; this could be interpreted as a critical region for 
designing peptides as potential therapeutic agents of type II diabetes.  
 
This is the first report describing the effect of peptides spanning the length of amylin for their 
ability to inhibit cytotoxicity of full length amylin. Amylin3–6, amylin9–13, amylin22–27, 
amylin29–34, and amylin derivative m5 which contains the sequence ST(N-Me)NV(N-
Me)G(N-Me)S(N-Me) were identified as potential inhibitors of amylin-mediated cytotoxicity. 
The only drawback to the non-methylated amylin derivatives would be their biological 
instability and for this reason the N-methylated peptide corresponding to the 29–34 region 
becomes significant. The next step in finding a potential therapeutic agent for type II diabetes 
would be further testing to evaluate the biodegradability of the N-methylated amylin 
derivative m5 followed by in vivo testing.  
 
In addition, a peptoid molecule that is based on the 29-34 region of amylin could also be 
evaluated as a potential inhibitor of amylin-mediated cytotoxicity. Peptoids are peptide 
analogs that contain N-substituted glycines and the R-groups on the amino group of each 
residue can be chosen to mimic a specific peptide sequence.[46] Sequence homology to 
amylin and in particular the 29-34 region, could allow association with full length amylin but 
since the R-groups are present on the amino group, the hydrogen bonding capacity of the 
peptide would be retarded, thus possibly preventing amylin aggregation. In addition, it has 
been suggested that peptoids may have reduced immunogenicity and good biostability [47], 




This is the first study that has synthesized amylin derivatives spanning the length of amylin 
and evaluated their effect on amylin-mediated cytotoxicity. It was observed that in general, 
the non-methylated peptides were better inhibitors of amylin-mediated cytotoxicity than their 
N-methylated counterparts. Interestingly, inhibition of amylin fibril formation did not 
correlate to inhibition of cytotoxicity which further supports the hypothesis that the oligomer 
is the toxic species of amylin. Due to its biostability, it can be suggested that the N-methylated 
amylin derivative ST(N-Me)NV(N-Me)G(N-Me)S(N-Me) has potential as a therapeutic agent 
of type II diabetes and further testing will be conducted using this derivative. 
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5.1 Abstract 
Amylin is a peptide that aggregates into species that are toxic to pancreatic beta cells, leading 
to type II diabetes. This study has for the first time quantified amylin association and 
dissociation kinetics (association constant (ka) = 28.7 ± 5.1 M
-1s-1 and dissociation constant 
(kd) = 2.8 ± 0.6 x 10
-4 s-1) using surface plasmon resonance (SPR). Thus far, techniques used 
for the sizing of amylin aggregates do not cater for the real time monitoring of unconstrained 
amylin in solution. In this regard we evaluated recently innovated nanoparticle tracking 
analysis (NTA). In addition, both SPR and NTA were used to study the effect of previously 
synthesized amylin derivatives on amylin aggregation and to evaluate their potential as a cell-
free system for screening potential inhibitors of amylin-mediated cytotoxicity. Results 
obtained from NTA highlighted a predominance of 100-300 nm amylin aggregates and 
correlation to previously published cytotoxicity results suggests the toxic species of amylin to 
be 200-300 nm in size. The results seem to indicate that NTA has potential as a new technique 
to monitor the aggregation potential of amyloid peptides in solution and also to screen 
potential inhibitors of amylin-mediated cytotoxicity. 
 




Full length human amylin (amylin) is a 37 amino acid long peptide which is released together 
with insulin from pancreatic beta cells.[1, 2] Accumulation of amylin can result in its soluble 
monomeric form aggregating into toxic oligomers and eventually fibrils [3-5], allowing it to 
be classified as an amyloidogenic peptide and implicating it in the development of type II 
diabetes.[2, 6-9] Inhibition or prevention of amylin aggregation and subsequent cytotoxicity 
has always relied on compounds that could bind to amylin [10-15], and numerous studies 
have investigated the multi-faceted dynamics of amylin aggregation.  
 
Techniques that have been used to elucidate the conformational change from a random coil or 
helical structure to a β-sheet structure and to provide a model for the secondary structure of 
amylin include circular dichroism spectroscopy [16, 17], Fourier transform infrared (FT-IR) 
spectroscopy [18], two-dimensional (2D) spectroscopy [19, 20], and solid state nuclear 
magnetic resonance (NMR).[21] Filtration assays [5, 16] were used to monitor the time-
dependent change in aggregate size but does not allow for real time monitoring of the 
aggregation process. For observation of the aggregation process in real time, atomic force 
microscopy (AFM) [22, 23] can be employed which generates quantitative data on the 
diameter as well as the growth rate of amylin aggregates. The latter mentioned amylin 
aggregation dynamics were also elucidated using scanning transmission electron microscopy 
(STEM).[17, 24, 25] 
 
Two other techniques that have been used to monitor amylin aggregation dynamics include, 
electrochemical analysis [26] which is based on the oxidation of tyrosine, and tryptophan 
triplet quenching [27] which as its name implies monitors the quenching of the triplet state of 
tryptophan by cysteine or disulfides. Although no quantitative data were presented, these 
techniques were used to study the rate of interaction between the chain termini of amylin and 
the kinetics of amylin aggregation respectively. A more recent study made use of the 
thioflavin T (ThT) dye and total internal reflection fluorescence microscopy to visualize 
amylin aggregation.[28] Although AFM and STEM data can be combined to generate 
association kinetics, none of the techniques mentioned above are independently capable of 
generating quantitative data on the association and dissociation kinetics of amylin. In 
addition, no study to date has monitored the change in size of aggregates that formed from 
unconstrained amylin in solution over real time.  
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From as early as 1994, surface plasmon resonance (SPR) technology has been used to 
determine the aggregation kinetics of amyloidogenic proteins.[29-31] Surface plasmon 
resonance can monitor protein-protein interaction and is based on the principle that the 
refractive index at a surface changes proportionally to the amount of molecules present on it 
which can be measured using an optical system.[32] Some of the advantages of SPR are that 
it allows for fibril growth to be monitored over minutes or even seconds, very low sample 
concentrations are required, and no peptide-labeling strategy is necessary thus permitting 
direct analysis of unmodified peptide sequences.[33] Moreover, quantitative data can be 
generated to express the rate of association as well as the dissociation kinetics. 
 
Of all the amyloidogenic proteins, amyloid beta (Aβ) interactions have been the most 
extensively studied using SPR [30, 33-46] followed by prion protein (PrP), which have been 
implicated in Alzheimer’s disease and transmissible spongiform encephalopathy (Prion 
diseases) respectively.[47-50] Initially Myszka et al. (1999) reported SPR as a suitable 
technique to assess the association and dissociation kinetics of Aβ aggregation.[51] 
Thereafter, SPR was employed to extensively characterize the aggregation kinetics of Aβ [33, 
37], and a SPR-based assay was subsequently developed to allow identification of small 
molecules that bind to Aβ and which could act as potential therapeutic agents against 
Alzheimer’s disease.[36] It was also reported that SPR could be used as a potential assay for 
screening anti-prion molecules.[48] For more details with respect to SPR investigations into 
Aβ aggregation an extensive review by Aguilar and Small (2005) is recommended.[52] 
However, up until now SPR-based studies into amylin aggregation are limited to the 
attachment of biotinylated-amylin derivatives to strepavidin-coated sensor chips.[53, 54]  
 
Jaikaran et al. (2004) evaluated the interaction of rat amylin and compounds present in the 
secretory granule of pancreatic beta cells such as insulin, somatostatin and proinsulin, with 
the sensor chip-bound biotinylated-amylin.[53] A similar SPR-based approach was employed 
by Wei et al. (2009) and in both of these studies, it was suggested that insulin inhibits 
formation of β-sheet structures by binding to biotinylated-amylin.[53, 54] The most recent 
study immobilized nanoparticles on a sensor chip and used SPR to evaluate the binding 
affinity of amylin for these particles.[55] However, the generated data was not indicative of 
the kinetics of amylin association and dissociation. In addition, a SPR-based strategy is yet to 
be evaluated as a potential cell-free selection system for inhibitors of amylin-mediated 
cytotoxicity. 
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Elucidation of the aggregation dynamics of amylin could also involve monitoring the change 
in size of the amylin aggregates. As mentioned earlier, other studies that have monitored the 
size of amylin aggregates made use of STEM or AFM which involves adsorption of 
aggregates onto copper grids or mica surfaces respectively.[5, 16, 17, 24, 25] Although these 
studies provided valuable insight into amylin aggregate structure, they did not allow for 
unconstrained real time monitoring of amylin aggregation. In addition, it has been observed 
that fibrils formed from unconstrained amylin in solution exhibit distinctly different 
morphologies from those propagated on a mica surface.[22, 23] It was suggested that the mica 
surface used in AFM could possibly impede coiling of fibrils around each other and thereby 
prevent formation of higher order fibrils.[22, 23] 
 
Another commonly used particle sizing technique but which does not involve attachment of 
the molecule to a solid support is dynamic light scattering (DLS). This technique is easy to 
perform and has been proven to produce accurate results in a short time.[56] Dynamic light 
scattering relies on the phenomenon that Brownian motion of particles causes fluctuations in 
their scattered light intensity which is proportional to the particle size. An alternative 
technique that makes use of the Brownian motion of particles for size determination is 
nanoparticle tracking analysis (NTA) which was developed by Malloy and Carr (2006).[57] 
The NTA technology makes use of a laser light scattering microscope and charge-coupled 
device (CCD) camera that visualizes and records nanoparticles. Thereafter NTA-based 
software is able to track nanoparticles that move under Brownian motion and relate the 
movement to its size using a formula (Equation 1) as derived by Filipe et al. (2010) [58] from 






where kB is the Boltzmann constant, and (x,y)
2
is the mean-squared speed of a particle at 
temperature T, in a medium of viscosity η with a hydrodynamic radius of rh. Thus, NTA can 
estimate the size of particles in a poly-disperse sample and was shown to be a suitable 
technique for monitoring protein aggregation.[58]  
 
To date, DLS has been used to size the monomeric form of amylin and the aggregated form of 
amylin derivatives.[60, 61] However, it should be mentioned that DLS and NTA technologies 
are yet to be employed to evaluate the oligomeric and fibrillar forms of amylin. 
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It is also noteworthy that cell-free systems such as circular dichroism (CD) [11, 13, 14, 62, 
63], FT-IR spectroscopy [11], transmission electron microscopy [11-13, 62-65], the ThT 
assay [12-14, 64-67] and sedimentation assays [12, 14, 62] cannot differentiate between the 
toxic oligomeric and non-toxic fibrillar forms of amylin and thus are used together with cell-
based assays for screening potential inhibitors of amylin-induced cytotoxicity. However, cell-
based systems can be time-consuming and extremely expensive as it is dependent on the 
growth rate of a particular cell line and is also labor-intensive, thus highlighting the need for a 
cell-free system for efficient routine screening of potential inhibitors of amylin-mediated 
cytotoxicity. 
 
In the present study we employ DLS, NTA and SPR strategies to evaluate the aggregation 
dynamics of amylin. Moreover the potential of these techniques as a new screening 
technology for inhibitors of amylin-mediated cytotoxicity was assessed by monitoring the 
effect of chemically synthesized human amylin derivatives on amylin-amylin interaction and 
correlating results to previously published cytotoxicity data.[68] NTA was also used to 
identify the size of the amylin aggregates that are probably responsible for amylin-mediated 
cytotoxicity. 
 
SPR-derived data indicates that the association kinetics of amylin is similar to that of Aβ1-40 
whilst it appears that amylin dissociates slower than Aβ1-40. Data generated from NTA of 
amylin samples co-incubated with each of its derivatives were found to correlate well with the 
ability of each amylin derivative to inhibit amylin-mediated cytotoxicity. In addition, NTA 
seemingly indicates that the size range of the toxic species of amylin is 200-300 nm. It can be 
tentatively suggested that NTA could be employed as a novel cell-free approach to monitor 
the aggregation of amyloidogenic peptides and for the screening of potential inhibitors of 
amylin aggregation and cytotoxicity. 
 
5.3 Materials and Methods 
5.3.1 Reagents 
All 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids and coupling reagents were 
purchased from GLS Biochem Systems, Inc. (China). The following protecting groups were 
used for the side chains of the amino acids; trityl (Trt) for asn, cys, gln, and his, t-butyl ether 
(tBu) for ser and thr, 2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl (Pbf) for arg, and t-
butyloxycarbonyl (Boc) for lys. The PAL-ChemMatrix resin was purchased from Matrix 
Innovation (Canada) and all solvents for synthesis and purification were of high performance 
liquid chromatography (HPLC) grade and were purchased from Sigma-Aldrich (U.S.A.). The 
CM5 sensor chip and the thiol coupling kit were purchased from BIAcore AB (Sweden). 
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5.3.2 Peptide synthesis 
For the SPR experiment, a modified version of human amylin (MA) was synthesized, wherein 
the first seven residues at the N-terminal of human amylin was replaced by the linker 
sequence CRKRK (Figure 5.1). This modification contains a cysteine residue at the N-
terminus to enable thiol coupling to the BIAcore sensor chip, thus allowing MA to be used as 
the ligand for the SPR-based experiment. Chemically synthesized human amylin (amylin) 
[69] was used as the analyte for the SPR experiments, as well as for the DLS and NTA 
experiments. 
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Figure 5.1 Primary sequences of chemically synthesized full length human amylin and 
modified amylin (MA). 
 
Modified amylin was synthesized on a 0.1 mmol scale using a CEM microwave peptide 
synthesizer as described previously.[69] Briefly, deprotection was performed using 20% 
piperidine in dimethyl formamide (DMF). The activator used in the synthesis was 0.5 M 2-
(1H-benzotriazole-1-yl)-1, 1, 3, 3-tetramethyluronium hexafluorophosphate (HBTU) in DMF, 
with 1 M N, N-diisopropylethylamine (DIPEA) in DMF serving as the activator base. The 
peptide was cleaved from the resin using 5% tri-isopropylsilane in trifluoroacetic acid (TFA) 
(v/v) for two hours. 
 
Amylin derivatives (Table 5.1) were synthesized as potential inhibitors of amylin-mediated 
cytotoxicity as previously reported [68] and their impact on amylin aggregation dynamics 
were investigated. 
 
Table 5.1 Sequence of chemically synthesized non-methylated and N-methylated amylin 
derivatives 
Amylin segment Non-methylated sequence N-methylated sequence 
Amylin3-6 NTAT (n1
#) NTAT* (m1#) 
Amylin9-13 TQRLA (n2
#) TQRLA* (m2#) 
Amylin15-20 FLVHSS (n3
#) FLVHSS* (m3#) 
Amylin22-27 NFGAIL (n4
#) NFGAIL* (m4#) 
Amylin29-34 STNVGS (n5
#) STNVGS* (m5#) 
#n1-n5 and m1-m5 are shorthand notations that are used to denote amylin derivatives. 
*N-methylated amino acids are underlined. 
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5.3.3 Peptide purification 
The modified amylin was purified on an ACE C18 preparative column (250  22 mm, 
Scotland) as previously described.[69] A dual-buffer system was employed, with TFA serving 
as the ion-pairing agent. The first buffer consisted of 0.1 % TFA/H2O (v/v) whilst the second 
buffer was composed of 0.1% TFA/acetonitrile (v/v). The peptides were eluted using a 
gradient of 0-90% of 0.1% TFA/acetonitrile (v/v) over 90 minutes with a flow rate of 20 
mL/min. The solvent from pooled peptide-containing fractions was evaporated to 20 mL and 
the samples were snap-frozen in liquid nitrogen and lyophilized. 
 
5.3.4 Peptide analysis 
The purified peptide was analyzed with an Agilent 1100 HPLC system fitted with a Waters 
XBridge C18 column, 250  3.6 mm as previously described.[69] Chromatography was 
performed over 90 minutes using a gradient of 0-90% of 0.1% TFA/acetonitrile (v/v) at a flow 
rate of 0.3 mL/min and the eluent was monitored at a UV wavelength of 215 nm. A Bruker 
electrospray ionization time-of-flight spectroscope (ESI-QTOF) in positive mode was used to 
obtain mass spectra (MS) and matrix assisted laser desorption ionization time-of-flight mass 
spectroscopy (MALDI-TOF MS) was performed with an Autoflex III instrument (Bruker) 
operated in positive mode with cyano-4-hydroxycinnamic acid being used as the matrix. 
 
5.3.5 Disaggregation method 
Disaggregation of amylin and its derivative MA were performed as previously described.[68] 
Pre-weighed amylin samples were solubilized in 200 µL hexafluoroisopropanol (HFIP):TFA 
solution (50:50, v/v), sonicated for 10 minutes and left overnight. The solvents were then 
removed under vacuum using a centrifugal evaporator for approximately 1-2 hours. 
Approximately 100 µL HFIP was added to the peptide, followed by vortexing and the solvent 
was removed by rotary evaporation for 1-2 hours. To remove all traces of TFA, the latter 
process was repeated twice using HFIP (100 µL). 
 
5.3.6 Amylin immobilization for surface plasmon resonance (SPR) 
All sensorgrams for SPR were performed on a BIAcoreX biosensor and analyzed using 
BIAevaluation version 4.1.1 software (BIAcore AB, Sweden). The running buffer for all 
SPR-based experiments were adapted from Jaikaran et al. (2004) [53] and contained 10 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 4 mM EDTA, 150 mM NaCl, 
0.005% Tween 20, and 5% dimethylsulfoxide (DMSO), pH 7.4. The following solutions were 
adapted from Liu et al. (2004) and Takahashi et al. (2010) [44, 70] for the 
regeneration/washing steps. Solution 1 contained 6 M guanidine hydrochloride (Gdn-HCl) in 
10 mM Tris-HCl (pH 8.0), solution 2 was made up of 5% DMSO in water (v/v), and solution 
3 was composed of 100 mM NaOH. 
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Attachment of MA to the CM5 sensor chip followed standard ligand thiol coupling conditions 
as suggested by the manufacturer. A flow rate of 10 μL/min was maintained for all 
immobilization steps, unless otherwise stated. The carboxymethyl dextran matrix on the CM5 
sensor chip was activated by injecting 40 μL of a 1:1 mixture of 200 mM N-ethyl-Nα-
[(dimethylamino)propyl]-carbodiimide (EDC) and 50 mM N-hydroxysuccinimide (NHS), 
followed by the addition of 40 μL of 80 mM 2-(2-Pyridinyldithio)-ethaneamine hydrochloride 
(PDEA) in 50 mM sodium borate buffer (pH 8.5). A 20 μL aliquot of 1 μM MA in 10 mM 
sodium acetate buffer (pH 5.0) was then injected into the activated flow cell. An aliquot (40 
μL) of 50 mM L-cysteine in 0.1 M sodium acetate and 1.0 M NaCl, pH 4.0 was then injected 
to eliminate free, unreacted maleimide groups so as to prevent non-specific binding. To 
remove non-covalently associated MA, the surface of the chip was washed sequentially with 
15 µL of each of the three wash solutions described above, whilst maintaining a flow rate of 
20 µL/min. The control flow cell was setup using the protocol described above with 
elimination of the MA attachment step and the three subsequent wash steps.  
 
5.3.7 Surface plasmon resonance analysis of amylin and its derivatives 
A flow rate of 5 μL/min was maintained for all subsequent SPR experiments, unless otherwise 
stated. To determine amylin aggregation kinetics, a concentration series (40-120 μΜ) of 
disaggregated amylin samples were solubilized in filter sterilized (0.22 μm, nylon) running 
buffer by sonication for five minutes and injected onto the sensor chip-immobilized amylin 
for 3 minutes. Dissociation kinetics was monitored for 360 seconds by allowing running 
buffer only to pass over the sensor chip surface. Whilst maintaining a flow rate of 20 μL/min, 
regeneration was achieved using 15 μL of solution 1 and solution 3 respectively. Triplicate 
injections of 40, 50, 60, 80 and 120 μΜ disaggregated amylin were analyzed in a random 
order with two regeneration steps being performed between each concentration. Curve fitting 
of each data set at varying concentrations were performed using BIAevaluation version 4.1.1 
software. 
 
To evaluate the effect of each amylin derivative on amylin-amylin interaction, stock solutions 
(1 mM) of each derivative was prepared in running buffer. Each amylin derivative was then 
added to lyophilized samples of disaggregated amylin to yield a final ratio of 50 μM:250 μM 
(amylin:amylin derivative). Mixtures of amylin and each of the amylin derivatives were 
sonicated for 5 minutes before 15 μL of each sample was injected onto sensor chip-
immobilized amylin. Dissociation was once again monitored for 360 seconds by allowing 
running buffer to flow over the sensor chip surface. Between each sample, regeneration was 
performed as described above.  
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All sensorgrams were double referenced, that is, responses were corrected with both blank 
buffer injections and the response from the reference flow cell. Double referencing was 
performed to remove system artifacts as recommended by Myszka (1999).[51] For samples 
containing a mixture of amylin and each of its derivatives, responses were also corrected with 
sensorgrams obtained from 15 μL injections of samples containing each amylin derivative 
only (250 μM). 
 
5.3.8 Dynamic light scattering (DLS) 
Dynamic light scattering experiments were performed in a Zetasizer NanoZS (Malvern 
Instruments Ltd., United Kingdom). To monitor the change in size of amylin aggregates 
during aggregation, a sample of disaggregated amylin was solubilized by sonication for five 
minutes in filter sterilized 10 mM sodium phosphate buffer, pH 7.4 containing 50 mM NaCl 
(Buffer A) to a final concentration of 50 μΜ and analyzed at various time points. To 
determine if lower concentrations of the sample affected the poly-dispersity index, serial 
dilutions of the 50 μΜ amylin sample were prepared in Buffer A and analyzed. Zetasizer 
version 6.30 software (Malvern Instruments Ltd., United Kingdom) was used to analyze and 
convert data sets obtained to apparent hydrodynamic diameters. 
 
5.3.9 Nanoparticle tracking analysis (NTA) 
NTA measurements were performed with a NanoSight LM20 instrument (NanoSight, United 
Kingdom) equipped with a 640 nm laser and a temperature controlled sample chamber. To 
monitor the change in size of amylin aggregates during aggregation, disaggregated amylin 
was solubilized by sonication for five minutes in Buffer A to a final concentration of 50 µM. 
The peptide was then injected into the sample chamber and allowed to equilibrate to 37C 
(approximately one minute) before 60 second video recordings were captured at ten minute 
intervals for the first hour and then at 24 hours. The sample temperature was maintained at 
37C for the entire duration of the experiment. These experimental conditions were similar to 
that used for a previously reported cytotoxicity experiment [68] thus allowing correlation of 
results obtained from the two techniques.  
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To assess the effect of the amylin derivatives on amylin aggregation, stock solutions (1 mM) 
of each amylin derivative was prepared in Buffer A. Each amylin derivative was then added 
to lyophilized samples of disaggregated amylin to give a final ratio of 50 μM:250 μM 
(amylin:amylin derivative). Mixtures of amylin and each of its derivatives were sonicated for 
5 minutes before being injected into the sample chamber. Once again, samples were 
maintained at 37C and 60 second video footage were recorded every ten minutes for the first 
hour and then at 24 hours. All videos were captured with the single shutter and gain modes. 
Analysis was performed using NanoSight NTA version 2.2 software with a viscosity setting 
of 0.70. All determinations were performed in duplicate with standard deviations displayed as 
error bars on the NTA graphs. 
 
5.3.10 Statistical analysis 
In this study, the means and standard deviations were employed in the unpaired t test to 
statistically compare the concentration of 100-150 nm, 150-200 nm and 200-300 nm 
aggregates in samples containing amylin only to that formed in samples containing a mixture 
of amylin and each of its derivatives. GraphPad InStat version 3 for Windows XP (GraphPad 
Software, U.S.A) was used for the statistical analysis and results were considered 
significantly different if p values were less than 0.05. 
 
5.4 Results 
5.4.1 Peptide synthesis 
As observed by MALDI-TOF analysis (Figure 5.2), MA was synthesized with high purity and 
a yield of 9% (35 mg). The linker sequence CRKRK in MA was selected and incorporated 
since the basic R-groups of the arginyl and lysinyl residues will repel each other under 
physiological conditions. Upon binding of MA to the sensor chip for SPR-based experiments, 
this linker region ensures that the 8-37 region of amylin will be a sufficient distance away 
from the surface of the chip and from each other, thereby allowing it to freely interact with the 
analyte. The linker sequence in MA replaced the 1-7 region of amylin since the 8-37 region 
alone was previously shown to exhibit a typical amyloidogenic β-sheet structure and formed 
fibrils with the same morphology as fibrils formed from full length amylin.[17, 71] In 
addition, solid state NMR models have revealed that the 1-7 region of amylin is not involved 
in the formation of β-sheet structures.[20, 21, 71] Moreover, a peptide analog of the 8-37 
region of amylin exhibited fibrillogenesis kinetics that was comparable to full length 
amylin.[72] Thus, it was strategized that MA would have a similar binding affinity as full 
length amylin thereby being suitable to study amylin-amylin interactions. 
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Figure 5.2 MALDI-TOF spectrum of modified amylin (MA). 
 
5.4.2 Surface plasmon resonance 
When disaggregated amylin was immobilized, a change of 640 response units (RU) was 
recorded, indicating that amylin attachment to the sensor chip was efficient since a similar 
immobilization density was observed during previous SPR-based kinetic studies of Aβ.[37] 
Once this was established, further experiments were performed to determine the kinetic rate 
constants of amylin aggregation. Samples of disaggregated amylin at various concentrations 
(40-120 μΜ) were analyzed and global fitting of the data using different types of interactions 
was performed using BIAevaluation version 4.1.1 software to determine the kinetic rate 
constants which include the association constant (ka) and dissociation constant (kd) (Table 
5.2). The three sets of data were fitted independently to verify reproducibility and it should be 
noted that all three replicates followed a similar trend (representative plot in Figure 5.3). 
 
Table 5.2 Binding kinetics of amylin obtained from SPR BIAevaluation data fitting software 
ka (M
-1s-1) 28.7 ± 5.1 * 
kd (s
-1) 2.8 ± 0.6 x 10-4 * 
* The kinetic data represents averages ± SD of triplicate samples. 
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The 1:1 Langmuir interaction (equation 1) was found to fit the generated data very well since 
the curves created from this type of interaction fit the observed plots very well (representative 
residual plots and fitted curves in Figure 5.3). This type of interaction could thus give the best 
representation of the kinetic data generated for amylin. In this interaction, one ligand (L) 
molecule interacts with one analyte (A) molecule and the resultant complex (LA) follows 
pseudo first-order kinetics. The rate equation 2 indicates that the amount of complex formed 
over time is proportional to ka and kd in the presence of excess analyte.[73, 74] As observed 
from the residual plots in Figure 5.3A, the chi2 values are less than 10 which is an acceptable 
value for good fitting of data as suggested by the BIAevaluation handbook. This confirms an 
alignment of the observed and expected data since they are within the noise range of the 
sensorgrams.[73]  
 



























Figure 5.3 Kinetic analysis of amylin aggregation as generated from SPR-based experiments. 
(B) Sensorgram plots of various concentrations (40-120 μM) of disaggregated amylin that 
were injected for three minutes to observe association and with dissociation being monitored 
for six minutes, whilst maintaining a flow rate of 5 μL/min. The black lines represent the 
global fit for association (30-155 s) and dissociation (235-510 s). (A) The residual plots of 
curve fitting, that is, the difference between the observed and calculated values for association 
and dissociation. The chi2 value for association was observed to be 3 whilst the chi2 value for 
dissociation was 3.7. 
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Analysis via SPR was used to establish the effect of the amylin derivatives on amylin-amylin 
interaction. The sensorgrams for the association and dissociation phases of amylin in the 
presence and absence of its N-methylated and non-methylated derivatives are illustrated in 
Figures 5.4 and 5.5. Of the non-methylated amylin derivatives, n1 appears to increase binding 
of amylin to sensor chip-bound amylin without having an appreciable effect on dissociation, 
whilst amylin derivatives n2, n3 and n5 displayed negligible effects on association of amylin 
to immobilized amylin and marginally increased dissociation (Figure 5.4A). The amylin 
derivative n4 was observed to markedly increase amylin association and decrease dissociation 
(Figure 5.4B). It is noteworthy that this derivative alone interacted strongly with surface-
bound amylin as evidenced by an increase in response units during association which 
decreased marginally during the dissociation phase (data not shown). Evaluation of the N-
methylated amylin derivatives show that m1, m2, m3, m4 and m5 do not have a significant 
effect on amylin association but rather appear to slightly increase dissociation of amylin from 
the sensor chip-immobilized amylin (Figure 5.5). However, it is noteworthy that SPR-
generated data on the effect of the amylin derivatives on amylin-amylin interaction did not 












Figure 5.4 SPR generated sensorgrams showing the effect of non-methylated (n1-n5) amylin 
derivatives on amylin interaction with sensor chip-immobilized amylin. Sample A is 
disaggregated amylin that was prepared in running buffer to a final concentration of 50 µΜ, 
whilst A+n1, A+n2, A+n3, A+n4, and A+n5 are samples containing a mixture of 
disaggregated amylin (50 μM) and a five times molar excess of each of the amylin derivatives 
respectively. The samples were injected onto the sensor chip for three minutes to observe 
association and dissociation was monitored for six minutes, whilst maintaining a flow rate of 
5 μL/min. 




Figure 5.5 SPR generated sensorgrams showing the effect of the N-methylated (m1-m5) 
amylin derivatives on amylin interaction with sensor chip-immobilized amylin. Sample A is 
disaggregated amylin that was prepared in running buffer to a final concentration of 50 µΜ, 
whilst A+m1, A+m2, A+m3, A+m4 and A+m5 are samples containing a mixture of 
disaggregated amylin (50 μM) and a five times molar excess of each of the amylin derivatives 
respectively. The samples were injected onto the sensor chip for three minutes to observe 
association and dissociation was monitored for six minutes, whilst maintaining a flow rate of 
5 μL/min. 
 
5.4.3 Dynamic light scattering 
Dynamic light scattering analysis of disaggregated amylin (50 µM) was performed after 
resuspension in Buffer A. Reports generated by the Zetasizer version 6.30 software recorded a 
poly-dispersity index of greater than 0.7, indicating that the sample is very poly-disperse and 
therefore reported no data. A similar outcome was observed during DLS analysis of samples 
containing lower concentrations of disaggregated amylin. 
 
5.4.4 Nanoparticle tracking analysis  
Nanoparticle tracking analysis was employed to evaluate the size of amylin aggregates that 
form in real time when disaggregated amylin samples are unconstrained in solution. Initial 
NTA of a 50 μM amylin sample established that a total concentration of 3.12 x 108 
aggregates/mL was present which is within the ideal concentration range (1-25 x 108 
aggregates/mL) for accurate NTA.[75] This concentration was thus selected for all further 
NTA experiments. 
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Taking resuspension, injection and equilibration times into consideration, the time lapse from 
addition of buffer to analysis was approximately ten minutes, making analysis of a zero time-
point impractical. Figures 5.6 and 5.7 illustrate that aggregates are present at the ten minute 
time-point, suggesting that amylin starts to aggregate almost immediately upon resuspension 
in buffer. The three major peaks indicate that the predominant aggregates are within the 
following size ranges, 100-150 nm, 150-200 nm and 200-300 nm which are represented by 
arrows a, b and c respectively (Figure 5.6). During the first 50 minutes, peaks in the size 
range 100-200 nm are not well defined indicating that there is a range of aggregates with sizes 
between 100-200 nm. As time progresses, the amylin aggregates clearly resolves into two 
distinct peaks that are indicated by arrows a and b (Figure 5.6). Further analysis on these size 
ranges were performed and are depicted in Figure 5.7. During the first hour, the number of 
100-150 nm, 150-200 nm and 200-300 nm aggregates decreased by more than 50% to a 
concentration of 2.5-3.0 x 107 aggregates/mL and thereafter remained stable up until 24 hours. 
 
 
Figure 5.6 NTA size distribution profile of disaggregated amylin (50 μM) in 10 mM sodium 
phosphate buffer, pH 7.4 containing 50 mM NaCl. The sample was maintained at 37C for the 
duration of the experiment. Video recordings (duration of 60 seconds) for NTA were taken at 
each time point using the single shutter and gain mode. Arrows labeled a, b and c indicates 
the predominant size range over 24 hours. 




Figure 5.7 NTA distribution of 100-150 nm, 150-200 nm and 200-300 nm aggregates that 
formed over time from disaggregated amylin (50 μM) in 10 mM sodium phosphate buffer, pH 
7.4 containing 50 mM NaCl. Samples were maintained at 37C for the duration of the 
experiments. Video recordings (duration of 60 seconds) for NTA were taken at each time 
point using the single shutter and gain mode. 
 
Each of the ten amylin derivatives were then individually co-incubated with disaggregated 
amylin and NTA was performed to evaluate their effect on amylin aggregation to the 
predominant sizes (Table 5.3). It appears that some of the non-methylated and N-methylated 
derivatives of amylin do exert a significant impact on the observed particle sizes at the 10 
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Table 5.3 Aggregate size distribution of amylin in the presence and absence of each of its 
derivatives 
 Concentration of aggregates (x 107 aggregates/mL) 














A# 5.7 2.9 5.4 2.5 7.0 2.7 
A+n1# 0.5* 0.9* 0.5* 1.1* 0.4* 0.8* 
A+n2# 4.3 1.5* 2.5 1.5* 3.4 2.1* 
A+n3# 2.0 3.4 1.2 2.1 1.4* 1.9* 
A+n4# 3.8 1.7 2.3 1.8 5.1 1.7* 
A+n5# 0.1* 2.4 0.1* 1.4* 0.5* 2.0* 
A+m1# 4.0 2.2 2.2 2.8 2.4* 4.3 
A+m2# 3.9 3.6** 2.4 7.9 2.6* 4.6 
A+m3# 2.1 5.9 1.6 3.9 2.1* 4.7 
A+m4# 2.7 4.1 1.5 2.8 1.6* 3.3 
A+m5# 0.9* 1.6* 0.8* 1.3* 0.8* 1.4* 
# A denotes amylin whilst A+n1, A+n2, A+n3, A+n4, A+n5, A+m1, A+m2, A+m3, A+m4 and A+m5 
denote amylin plus each of its derivatives. 
* Statistical analysis showed that this concentration of aggregates was significantly less (p<0.05) than 
that of samples containing amylin only. 
** Statistical analysis showed that this concentration of aggregates was significantly more (p<0.05) 
than that of samples containing amylin only. 
 
When disaggregated amylin was co-incubated with its derivative n1, the concentration of 
aggregates in the three size ranges for the entire duration of the experiment was significantly 
less than that observed in samples containing disaggregated amylin only. At the ten minute 
time interval, the concentration of 100-150 nm, 150-200 nm and 200-300 nm aggregates in 
the presence of derivatives n2 and n4 were not significantly different from that of samples 
containing disaggregated amylin only. However, after a 24 hour period it was found that the 
concentration of 200-300 nm aggregates were significantly less in samples containing 
disaggregated amylin and either derivative n2 or n4 than that of amylin only samples. 
Analysis of samples containing disaggregated amylin and the derivative n3 illustrate that at 
the start of the experiment there is a small amount of aggregates of all size ranges which 
increases only marginally over 24 hours. A similar trend was observed in samples containing 
amylin and its derivative n5. 
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When compared to samples containing disaggregated amylin only, the derivatives m1, m2, 
m3 and m4 were found to have no significant effect on amylin aggregation since after 24 
hours, the amount of 100-150 nm, 150-200 nm and 200-300 nm aggregates formed in the 
presence of each of these derivatives were similar to or more than the number of aggregates 
present in samples containing disaggregated amylin only. In the presence of derivative m5, 
there are significantly fewer amylin aggregates of all size ranges that form over the entire 
duration of the experiment when compared to samples containing amylin only. 
 
5.5 Discussion 
Whilst the kinetics of Aβ interactions are known, only limited data regarding human amylin-
based aggregation is available. Although previous microscopy-based studies (AFM and 
STEM) have reported on the size of amylin oligomers, there currently exists no information 
with respect to the magnitude of free fibrillar structures formed by amylin in solution. The 
data presented herein sheds some light on the above mentioned amylin parameters thereby 
promoting a greater understanding of amylin aggregation, a potential causative agent of type 
II diabetes. 
 
Data fitting of results from SPR-based studies using various concentrations of disaggregated 
amylin illustrate that amylin association and dissociation kinetics follow a 1:1 Langmuir 
association trend which is the simplest model for a 1:1 interaction between analyte and an 
immobilized ligand. The observed amylin association constant (ka) of 28.7  5.1 M-1s-1 can be 
interpreted as 0.035 complexes of amylin being formed per second in a one molar solution of 
amylin. An observed amylin dissociation constant (kd) of 2.8  0.6 x 10-4 s-1 suggests that 
under experimental conditions, it takes approximately 60 minutes for the complete 
dissociation of free amylin from sensor chip-immobilized amylin.  
 
Previous quantitative studies using STEM postulated that the mass-per-length (MPL) of an 
amylin protofibril is 10 kDa/nm [24] and AFM studies have shown that amylin grows at a rate 
of 1.1 nm/minute.[22] From these studies by Goldsbury et al. (1997 and 1999) it can be 
estimated that the approximate rate of amylin aggregation is 11 kDa/minute.[22, 24] As 
indicated by SPR-generated data of this study, 0.035 complexes of amylin form per second 
which translates to 2.1 complexes being formed per minute. This implies an aggregation rate 
of 8.2 kDa/minute (wherein a single amylin molecule of 3.9 kDa is added per complex). The 
SPR-derived amylin association kinetics generated in this study seemingly correlates to that 
previously reported by Goldsbury et al. (1997 and 1999) [22, 24] whom employed a similar 
strategy of pre-binding amylin to a solid support and monitoring association kinetics of 
amylin that is free in solution. 
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Since amylin and Aβ share similar structural properties of amyloidosis [5] it is opportune in 
this study to compare their association and dissociation kinetics. Aβ kinetics generated from 
previous SPR-based experiments revealed an association rate of 0.01 complexes per 
second.[37] Global fitting of the SPR data also found that Aβ dissociation follows the first 
order kinetic model with a kd of 2.23 x 10
-3 s-1.[37] This was further supported by a recent 
SPR-based Aβ study that determined a ka of 0.01 complexes per second for Aβ association 
following first order kinetics, whilst the kd was 9.2  1.3 x 10-4 s-1.[76] It is noteworthy that 
the former SPR-based evaluation of Aβ was performed under similar conditions to those used 
in the present study.[37] Both SPR-based studies on Aβ kinetics have established that fewer 
complexes of Aβ are formed over time.[37, 76] In addition, Aβ was revealed to have a faster 
dissociation time than amylin (7.5 and 18 minutes versus 60 minutes).[37, 76] 
 
The data presented herein complements previously published association kinetics of amyloid 
aggregation whilst differences were observed in the dissociation kinetics. This could indicate 
that even though amylin and Aβ share similarities in their conformational properties of 
aggregation, having non-identical sequences could result in different interactions being 
responsible for stabilizing the aggregated structure, thereby accounting for differences in their 
dissociation kinetics. According to a model developed by Petkova et al. (2006), the 12-21 and 
30-40 regions of the Aβ peptide form the β-sheet structure whilst the 22-29 region is 
responsible for forming the β-strand turn.[77] These regions contain predominantly 
hydrophobic amino acids and it has been suggested that the only hydrophilic interaction could 
be present between the oppositely charged side chains of asp and lys, thereby implying that 
only hydrophobic interactions are responsible for stabilizing the structure of aggregated 
Aβ.[21, 77] In contrast, NMR studies on amylin propose that there are hydrophobic 
interactions between the 15-17 and 23-27 region of amylin whilst inter-chain hydrophilic 
(electrostatic) interactions could be present between the 28-31 regions of amylin.[21] It is thus 
probable that both hydrophobic and hydrophilic interactions contribute to stabilization of the 
β-sheet structure of amylin and since hydrophilic interactions are stronger than hydrophobic 
interactions, this could most likely account for the longer dissociation time of amylin as 
observed in the present study. In addition, the SPR-derived aggregation kinetics of Aβ that 
have been described above was generated using the 1-40 form of Aβ which was previously 
shown to aggregate much more slowly than the 1-42 form of Aβ.[78] 
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In a previous study, we reported on N-methylated and non-methylated derivatives of amylin 
as potential inhibitors of in vitro amylin-mediated cytotoxicity.[68] In this SPR-based study 
these derivatives were co-incubated with disaggregated amylin so as to evaluate the effect of 
the amylin derivatives on the binding affinity of free amylin in solution to sensor chip-bound 
amylin and to subsequently determine if SPR could be used as a screening technique for 
inhibitors of amylin-mediated cytotoxicity. Of the non-methylated amylin derivatives only 
derivative n4 was found to associate with surface-bound amylin and hence had a significant 
effect on amylin:immobilized amylin interaction by increasing association and decreasing 
dissociation. Interestingly, this peptide is an analog of the 22-27 region of amylin that was 
previously observed to increase fibril formation [62] and to associate into β-sheet structures 
that coil around each other to form typical amyloid fibrils.[18] This region also covers the 25-
29 and 22-29 regions of amylin, which have been described as the most amyloidogenic region 
of amylin.[60, 79] A predictive model of amylin fibril formation also suggests that the 22-27 
region could be involved in formation of β-sheets.[80] Hence, it can be tentatively implied 
that the constituent amino acids of this region promote inter-chain hydrogen bonding 
interactions between carbonyl-imino dipoles, thereby facilitating binding of free amylin to the 
n4 derivative. It seems plausible that these aggregates containing amylin and its derivative n4 
would then interact with surface-immobilized amylin resulting in the observed higher 
association kinetics. 
 
Based on analysis of the SPR-generated data, it appears that the N-methylated amylin 
derivatives facilitate dissociation of amylin from sensor chip-bound amylin. A probable 
suggestion is that the introduction of the bulky methyl group onto the amide nitrogen of an 
amino acid prevents inter-chain hydrogen bonding interactions between carbonyl-imino 
dipoles and also provides steric hindrance, thereby destabilizing the β-sheet structure of 
amylin. This scenario is supported by previous investigations into peptide derivatives that 
could potentially inhibit fibrillogenesis of amyloidogenic peptides.[10, 11, 81, 82] 
 
However, SPR-generated data on the effect of the amylin derivatives on amylin-amylin 
interactions could not be correlated to previously reported outcomes of the potential of these 
amylin derivatives as inhibitors of amylin-mediated cytotoxicity.[68] In support of this, a 
similar observation was reported by Lee et al. (2005) [83] who found that increased binding 
of a molecule to Aβ does not necessarily indicate that the molecule has a capacity to reduce 
cytotoxicity. In addition, even though insulin has been reported to inhibit fibril formation, 
SPR-based experiments recorded a change of only 15 response units during binding of insulin 
to sensor chip-bound biotinylated amylin. [53] It is thus suggested that SPR cannot be used as 
a technique to screen potential inhibitors of amylin-mediated cytotoxicity. 
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Hence, both DLS and NTA strategies which allows for real-time monitoring of aggregation 
dynamics in solution were subsequently employed to evaluate the effect of these amylin 
derivatives on the size of amylin aggregates formed over a 24 hour period and to determine if 
DLS and NTA-generated data could be correlated to cytotoxicity results.  
 
Dynamic light scattering analysis of various concentrations of disaggregated amylin alone 
yielded no results since all samples were indicated as poly-disperse and thus not suitable for 
DLS. The limitation of DLS to accurately size amylin aggregates appear to stem from the 
inherent principle of the technique which is based on the concept that the intensity of light 
scattered from particles is proportional to its size. Since larger particles will scatter more light 
than smaller particles, small particles will be obscured by large ones and thus DLS will not be 
able to accurately size particles in a poly-dispersed sample.[58] Our observation is also 
supported by light scattering data on the amyloidogenic proteins Aβ [84] and prion protein 
[85], both of which have also shown that these samples were poly-disperse. 
 
However, NTA proved to be more successful in sizing amylin aggregates. Nanoparticle 
tracking analysis of samples containing disaggregated amylin only detected aggregates at the 
first 10 minute time-point, which seems to be consistent with previous reports using other 
technologies that have demonstrated almost instantaneous aggregation of amylin.[16, 86, 87] 
As described above, the highest concentration of amylin aggregates fall into the size ranges 
100-150 nm, 150-200 nm and 200-300 nm for the duration of the experiment. Moreover, the 
concentration of these aggregates decreases by more than 50% within the first hour and then 
remained constant until 24 hours, suggesting that complete aggregation of amylin occurs 
within the first hour. Since it has been reported extensively that an incubation period of 20-24 
hours is sufficient for amylin to facilitate cytotoxicity [11-13, 16, 18, 64, 68], it can be 
suggested that either the 100-150 nm, 150-200 nm or 200-300 nm aggregates represent the 
toxic species of amylin. 
 
Results obtained from NTA of samples containing disaggregated amylin and its derivative n1 
imply that this derivative could inhibit fibrillogenesis of amylin or conversely facilitate rapid 
aggregation of amylin into large aggregates that are out of the detection range (30-1000 nm) 
of NTA.[58] It was previously shown that the 1-7 region of amylin is in a random coil 
conformation and could have a modulating effect on amylin aggregation, that is the 
amyloidogenic nature of amylin is increased if this region is excluded from the amylin 
sequence.[71] It thus appears that the derivative n1 which is an analog of the 3-6 region of 
amylin could potentially delay fibril formation. 
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Based on NTA-generated data, it can be construed that the derivatives n2 and n4 enhances 
amylin fibril formation to an aggregate size greater than 1000 nm since the concentration of 
200-300 nm aggregates are significantly less in samples containing disaggregated amylin and 
either derivative n2 or n4, than that of samples containing disaggregated amylin only. 
Analysis of samples containing disaggregated amylin and either the derivative n3 or n5 
suggest that these derivatives could also possibly increase or severely impede amylin 
aggregation since at the start of the experiment there is a small amount of aggregates of all 
size ranges which increases only marginally over 24 hours. 
 
In 2009, Shim et al. proposed a model which demonstrates that residues 8, 13, 17, 25, 27 and 
32 act as nucleation points for formation of β-sheets.[19] The amylin derivatives n2, n3, n4 
and n5 each contain at least one of the proposed nucleation sites thus implying that these 
derivatives have the inherent potential to facilitate formation of β-sheet structures thereby 
promoting the formation of fully aggregated amylin in a short space of time. In addition, these 
amylin derivatives also span regions of amylin that have previously been reported to form β-
sheet structures.[11, 17, 18, 21, 60, 71, 79, 80, 88, 89] It is noteworthy and in keeping with 
this hypothesis, that a previous report showed that fibril formation of full length amylin was 
enhanced in the presence of amylin derivatives n3 and n4 which are analogs of the 15-20 and 
22-27 regions of amylin respectively.[62, 90] These previous findings would thus account for 
the potential of derivatives n2, n3, n4 and n5 to increase fibrillogenesis. 
 
However, further NTA-generated data indicate that the amylin derivatives m1, m2, m3 and 
m4 had no significant effect on amylin aggregation which is supported by a previous 
observation that the introduction of N-methylated amino acids into peptides does not always 
result in inhibition of fibril formation.[81] In contrast, analysis of samples containing 
disaggregated amylin and derivative m5 suggest that this derivative either delays or increases 
amylin aggregation. Since the derivative m5 contains bulky methyl groups, it is most likely 
that these groups provide steric hindrance when the derivative binds to amylin thereby 
destabilizing β-sheet structures. Thus, derivative m5 could possibly delay amylin aggregation. 
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Comparison of NTA-generated data to previously published reports implies that the amylin 
derivatives n1 and m5 inhibits fibrillogenesis whilst the derivatives n2, n3, n4 and n5 have the 
tendency to increase fibrillogenesis of amylin to an aggregate that is larger than 1000 nm. It is 
noteworthy that these 1000 nm aggregates are out of the detection range of NTA and could 
represent the fully aggregated form of amylin which has previously been reported to be non-
toxic.[91-96] In the presence of amylin derivatives n1, n2, n3, n4, n5 and m5, the 
concentration of 200-300 nm amylin aggregates was significantly lower than in samples 
containing amylin only at 24 hours. These derivatives were also previously reported to reduce 
amylin-mediated cytotoxicity by more than 40%.[68] Derivatives m1, m2, m3 and m4 were 
previously shown not to have an inhibitory effect on amylin-mediated cytotoxicity [68] and 
the concentration of 200-300 nm aggregates in samples containing disaggregated amylin and 
each of these derivatives were recorded to be similar to or more than the concentration of 
aggregates in samples containing disaggregated amylin only (≥ 2.7 x 107 aggregates/mL). 
Based on these observations it can thus be tentatively suggested that the 200-300 nm particle 
is the toxic species of amylin. 
 
This study is the first to report on real time monitoring of the aggregation of unconstrained 
amylin in solution. Furthermore, amylin was used in its unmodified form, thereby providing 
an insight into the behavior of amylin under experimental conditions that are closely 
representative of those employed in mammalian cell line-based cytotoxicity studies. Data 
obtained also suggest that a critical concentration of 200-300 nm aggregates for amylin-
mediated cytotoxicity is more than 2.1 x 107 aggregates/mL. As mentioned previously, cell-
based systems for screening potential inhibitors of amylin-mediated cytotoxicity can become 
cumbersome and time-consuming. Thus, after further optimization and verification studies, 




This study has demonstrated the suitability of SPR for use in pursuit of the association and 
dissociation rates of amylin aggregation kinetics. In addition, nanoparticle tracking analysis 
offers an attractive strategy as a rapid evaluative cell-free tool to assess inhibitors of amylin-
mediated cytotoxicity. Moreover NTA can also be used as a technique that caters for real time 
monitoring of the amylin aggregation process whilst it continues unconstrained in solution. 
Importantly, the data from this study suggests that the size of toxic species of amylin is 
approximately 200-300 nm. 
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6.1 Abstract 
Amylin has been implicated in type II diabetes due to its inherent property to misfold into 
toxic aggregates. Although it has been shown that amylin interacts with cell membranes, no 
study to date has monitored the association process using a direct approach. The present study 
uses confocal microscopy to identify the localization of carboxyfluorescein-labeled amylin in 
RIN-5F cells. In addition, the size of the aggregates that forms were evaluated using 
nanoparticle tracking analysis (NTA). In support of previous findings, amylin was observed to 
interact with and remain associated to the cell membrane. The cell membrane-associated 
aggregates spanned a size range of 130-800 nm. 




Misfolding of peptides or proteins into toxic oligomers and fibrils result in a number of 
diseases collectively classified as amyloid diseases.[1-5] Of these, type II diabetes and 
Alzheimer’s disease are currently the most prevalent in society.[5] In type II diabetes, the 
peptide that is implicated in disease progression is amylin which is also referred to as islet 
amyloid polypeptide.[1-3, 6] Amylin is composed of 37 amino acids with a disulfide bridge 
between residues 2 and 7 (Figure 6.1), and aggregates into oligomers that are in a β-sheet 
conformation and which are toxic to pancreatic beta cells.[1-3, 7-13] Although there has been 
extensive research on potential inhibitors of amylin-mediated cytotoxicity, most of these 
studies have interrogated molecules that bind to amylin, which subsequently inhibits 
fibrillogenesis.[10, 13-31] However, to the best of our knowledge, there is currently no 
inhibitor of amylin aggregation that is a potential therapeutic agent for type II diabetes and 
which is under consideration for clinical development.[32] In an attempt to unravel its cellular 
pathway, it would be strategically beneficial to map the cellular localization of amylin 
aggregates so as to effect design of inhibitors of amylin aggregation and toxicity. 
 
K C N T A T C A T Q R L A N F L V H S S N N F G A I L S S T N V G S N T Y
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Figure 6.1 Primary structure of human amylin with a disulfide bond between amino acid 
residues 2 and 7. 
 
Initial studies on amylin localization employed immunogold labeling and showed that amylin 
is present in lipofuscin bodies in pancreatic beta cells of diabetic patients.[6] Subsequent 
studies suggested that amylin is in close proximity to the external cell surfaces, namely the 
cell membrane and islet capillaries.[33-39] However, none of these studies evaluated amylin 
localization in an in vitro mammalian cell-based system. 
 
The study herein, attempts to describe the real time in vitro cellular tracking of 
carboxyfluorescein-labeled amylin (carboxy-amy) aggregates in the rat pancreatic beta (RIN-
5F) cell line. This cell line was selected as it represents the in vivo cytotoxic target of amylin 
aggregates and thus observations could provide an insight into what occurs in the biological 
scenario. The advantages of the proposed strategy are that it employs direct visualization of 
amylin localization and hence precludes the use of multiple-labeling steps and also limits the 
possibility of non-specific interactions. Nanoparticle tracking analysis (NTA) was also 
performed to concisely estimate the size of amylin aggregates that formed. 
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Most studies up until now have incorporated an indirect labeling approach using Congo red to 
distinguish amylin aggregates or used other dyes to identify cellular components.[40-43] 
Congo red has been suggested to identify amyloid aggregates by binding to its β-sheet 
structure.[44, 45] Congo red was however demonstrated to bind non-specifically to cellular 
membranes [42], possibly since some membrane proteins are in a β-sheet conformation. In 
addition, Congo red was found to decrease both the rate of amylin fibrillogenesis and its 
cytotoxic effect.[18, 28] Hence, it is evident that Congo red interacts with amylin and it can 
therefore be suggested that studies making use of this dye to localize amylin may have 
resulted in incorrect data interpretation. In addition, other dyes that were used to identify 
cellular components could potentially affect amylin-amylin interaction and thus an indirect 
labeling approach to study amylin localization would not be truly representative of an in vivo 
system. 
 
One of the indirect amylin-labeling studies transfected the Simian fibroblast cell line (Cos-1) 
with vectors that express human amylin, and performed multiple labeling steps involving 
rabbit anti-amylin antiserum and sandwich labeling using the Oregon Green fluorochrome 
(GAR-FITC) to track amylin.[40] This study proposed that amylin is localized in the peri-
nuclear region of cells, in particular the endoplasmic reticulum and Golgi apparatus.[40] 
Another indirect labeling approach used Congo red to pin-point amylin aggregates and the 
water soluble dye carboxyfluorescein to determine membrane integrity.[41] This study 
reported that membrane lipids are incorporated into the amylin aggregates during amyloid 
formation resulting in membrane leakage of giant unilamellar vesicles (GUVs) and the rat 
insulinoma tumor (RIN) cell line.[41] However, an interesting observation from this study 
was that membranes remained intact when pre-formed fibrils were added to the GUVs and 
RIN cells thus suggesting that monomeric or oligomeric amylin binds to membranes.[41] 
 
It is noteworthy that even with the emergence of confocal microscopy-based experiments; 
fluorescent tags have not been extensively used for in vitro studies involving amylin 
localization. However, their ability to generate highly selective and sensitive results using 
simple experimental conditions has not gone unnoticed. To date, fluorescent-based 
investigative techniques have been primarily employed to study amylin aggregation dynamics 
in cell-free environments.[21, 22, 36, 46-50] 
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To the best of our knowledge, the only study that made use of fluorescent-labeled amylin to 
explore amylin localization was initiated by Radovan et al. (2009).[42] Their study employed 
a dual-fluorescent strategy that incorporated both Bodipy-labeled amylin and the membrane 
specific dye Texas red-DHPE. The results indicated that amylin was inserted into the 
membranes of rat insulinoma beta (INS-1E) cells and artificial model raft GUVs synthesized 
from DOPC:DPPC:cholesterol 1:2:1.[42] Although data suggested that membrane lipids were 
incorporated into the growing amyloid fibril, the Texas red-DHPE dye could potentially affect 
amylin aggregation kinetics thus resulting in incorrect data interpretation.[42]  
 
Interestingly, the study herein is the first to report on a direct fluorescent-based approach for 
the cellular localization of amylin. Importantly, carboxyfluorescein labeling of human amylin 
was shown to have no significant effect on the aggregating potential of amylin. It can thus be 
suggested that this modified form of amylin can be used in fluorescence-based experiments to 
probe amylin aggregation dynamics and its interaction with mammalian cells grown in 
culture. The data seems to show that carboxy-amy is predominantly associated with the cell 
membranes of RIN-5F cells. The size of aggregates that formed in the presence of the 
pancreatic beta cells was shown to span the size range of 130-800 nm. 
 
6.3 Materials and Methods 
6.3.1 Reagents 
All 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids and coupling reagents were 
purchased from GLS Biochem Systems, Inc. (China). The following protecting groups were 
used for the side chains of the amino acids: trityl (Trt) for asn, cys, gln, and his, t-butyl ether 
(tBu) for ser and thr, 2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl (Pbf) for arg, and t-
butyloxycarbonyl (Boc) for lys. The PAL-ChemMatrix resin was purchased from Matrix 
Innovation (Canada). High performance liquid chromatography (HPLC) grade solvents for 
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6.3.2 Peptide synthesis 
As proposed by Fulop et al. (2001), carboxyfluorescein-labeled amylin was synthesized using 
standard Fmoc-based solid phase protocol.[51] Full length amylin was synthesized on a 0.1 
mmol scale using a CEM microwave peptide synthesizer as previously described.[52] Briefly, 
deprotection was performed using 20% piperidine in dimethyl formamide (DMF). The 
activator used in the synthesis was 0.5 M 2-(1H-benzotriazole-1-yl)-1, 1, 3, 3-
tetramethyluronium hexafluorophosphate (HBTU) in DMF, with 1 M N, N-
diisopropylethylamine (DIPEA) in DMF serving as the activator base. Oxidation to form the 
Cys-2 to Cys-7 disulfide bridge was performed as previously described.[52] Briefly, 
unoxidised resin-bound amylin was allowed to bubble in methanol (3 mL) in a sintered glass 
bottom reaction vessel and iodine dissolved in methanol (approximately 5 mL) was added 
drop-wise until a faint yellow color developed. A washing step using DMF was performed, 
followed by coupling of 5(6)-carboxyfluorescein to the N-terminus of the resin-bound amylin. 
Coupling was performed for 20 hours using a ten times molar excess of 5(6)-
carboxyfluorescein with N-[(dimethylamino)-1H-1,2,3-triazolo[4,5-b]pyridino-1-
ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HATU) and DIPEA in 
DMF serving as the activator and activator base respectively. The peptide was subsequently 
cleaved from the resin using 5% tri-isopropylsilane in trifluoroacetic acid (TFA) for two 
hours. Chemically synthesized human amylin (amylin) was used as the control for 
transmission electron microscopy (TEM) and NTA.[52] 
 
6.3.3 Peptide purification 
Carboxy-amy was purified on an ACE C18 preparative column (250  22 mm, Scotland) as 
previously described.[52] A dual-buffer system was employed, with TFA serving as the ion-
pairing agent. The first buffer consisted of 0.1% TFA/H2O (v/v) and the second buffer 
contained 0.1% TFA/acetonitrile (v/v). The peptides were eluted using a gradient of 0-90% 
buffer B over 90 minutes with a flow rate of 20 mL/min. The solvent from pooled peptide-
containing fractions was evaporated to 20 mL and the samples were snap-frozen in liquid 
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6.3.4 Peptide analysis 
The purified peptide was analyzed with an Agilent 1100 HPLC system fitted with a Waters 
XBridge C18 column, 250  3.6 mm as previously described.[52] Chromatography was 
performed over 90 minutes using a gradient of 0-90% of 0.1% TFA/acetonitrile (v/v) at a flow 
rate of 0.3 mL/min and the eluent was monitored at a UV wavelength of 215 nm. A Bruker 
electrospray ionization time-of-flight spectroscope (ESI-QTOF) in positive mode was used to 
obtain mass spectra (MS) and matrix assisted laser desorption ionization time-of-flight mass 
spectroscopy (MALDI-TOF MS) was performed with an Autoflex III instrument (Bruker) 
operated in positive mode with cyano-4-hydroxycinnamic acid being used as the matrix. 
 
6.3.5 Disaggregation method 
Disaggregation of carboxy-amy was performed as previously described.[52] Pre-weighed 
amylin samples were solubilized in 200 µL hexafluoroisopropanol (HFIP):TFA solution 
(50:50, v/v), sonicated for 10 minutes and left overnight. The solvents were then removed 
under vacuum using a centrifugal evaporator for approximately 1-2 hours. Approximately 100 
µL HFIP was added to the amylin, followed by vortexing and the solvent was removed by 
rotary evaporation for 1-2 hours. To remove all traces of TFA, the latter process was repeated 
twice using HFIP (100 µL). 
 
6.3.6 Transmission electron microscopy (TEM) 
Carboxy-amy and amylin were disaggregated as described above and dissolved in filter 
sterilized 10 mM sodium phosphate buffer, pH 7.4 containing 50 mM NaCl (Buffer A) to a 
final concentration of 30 µM. Samples were incubated at 37C and at specific time points 2 
µL aliquots of each sample were transferred onto formvar coated carbon-stabilized copper 
grids. After drying for one minute, excess liquid was blot dried and samples were stained with 
2% (w/v) uranyl acetate for 30 seconds. Samples were blot dried again before being analyzed 
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6.3.7 Confocal microscopy 
The RIN-5F cell line (European Collection of Cell Cultures, Sigma-Aldrich) was cultured in 
RPMI 1640 growth medium containing 10% heat-inactivated fetal bovine serum, 2 mM 
glutamine, 1 mM sodium pyruvate, 25 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl] 
ethanesulfonic acid (HEPES), and 0.1 mg/mL penicillin/streptomycin, and thereafter plated at 
a density of 4 x 104 cells into 35 mm glass bottom petri dishes containing 14 mm micro wells 
(kindly donated by Dr Celia Snyman, University of KwaZulu-Natal). After an incubation 
period of 24 hours, spent media was replaced with fresh media. To establish if 
carboxyfluorescein was susceptible to photo bleaching effects, carboxyfluorescein only (2.54 
μM, equivalent to the amount of carboxyfluorescein present in 30 μΜ of carboxy-amy) was 
added to the RIN-5F cells and monitored over time. Images were viewed and captured with a 
Zeiss 710 laser-scanning confocal microscope and Zeiss LSM 710 software at 10 minute 
intervals for the first hour and then every 30 minutes up until three hours, using a 63x oil 
immersion objective. Twelve slices at different focal points were captured at each time 
interval. A 488 nm argon laser was used for excitation of the fluorophore whilst emission was 
captured at 520 nm. Images were also simultaneously captured using differential interference 
contrast microscopy (DIC). To track the cellular localization of carboxy-amy, RIN-5F cells 
were grown and plated as described above. After an incubation period of 24 hours, spent 
media was removed and carboxy-amy was dissolved in growth medium and added to the cells 
to a final concentration of 30 µM. At the end of the experiment, growth medium was 
recovered from the samples and later analyzed using NTA. All experiments were performed 
in duplicate with the temperature of the sample chamber set to 37°C. Confocal microscopy 
images were processed using ImageJ version 1.47d software (U. S. National Institute of 
Health, U. S. A.). 
 
6.3.8 Nanoparticle tracking analysis (NTA) 
NTA measurements were performed with a NanoSight LM20 instrument (NanoSight, 
Amesbury, United Kingdom) equipped with a 488 nm laser for exciting the 
carboxyfluorescein tag and a temperature controlled sample chamber set at 37C. To establish 
if the carboxyfluorescein tag aggregates on its own, carboxyfluorescein only (2.54 μM, 
equivalent to the amount of carboxyfluorescein present in 30 μM of carboxy-amy) was 
prepared in Buffer A and NTA performed by recording 60 second videos with the single 
shutter and gain modes. Analysis was performed using NanoSight NTA 2.2 software with a 
viscosity setting of 0.70. Samples recovered from confocal microscopy experiments were 
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captured and analyzed using NTA as described above. To monitor the aggregation dynamics 
of carboxy-amy over time, disaggregated peptide was diluted in Buffer A and sonicated for 
five minutes to yield a concentration of 30 μM before being injected into the sample chamber. 
Sample temperatures were allowed to equilibrate to 37C (approximately one minute) before 
60 second video recordings were taken at specific time points (every ten minutes for the first 
hour and then every 30 minutes up until three hours). Videos were captured and analysis 
performed as described above. 
 
6.4 Results 
In developing a suitable fluorescent strategy that will enable real time tracking of the 
interaction of amylin aggregates with cellular components it was deemed critical that the 
chemical modification should not interfere with its amyloidogenic potential. In this regard, the 
N-terminal lysine residue was selected as a suitable site of attachment of the fluorophore since 
there is general agreement that the N-terminal region of amylin is not involved in amylin fibril 
formation.[53, 54] Carboxyfluorescein was chosen as a suitable fluorophore as it was 
previously reported that a fluorescein label at the N-terminal of full length amylin [21] or on 
Aβ, the amyloidogenic peptide responsible for Alzheimer’s disease, had no significant effect 
on the amyloidogenic properties of these peptides.[53, 54] Moreover, some of the advantages 
that are associated with the use of carboxyfluorescein (Figure 6.2) are its high molar 
absorbtivity, excellent fluorescent quantum yield, good solubility in water and an excitation of 
494 nm, close to the 488 nm spectral line of the argon laser which makes it suitable for 
confocal microscopy imaging.[55] As illustrated in Figure 6.3, carboxyfluorescein-labeled 










Figure 6.2 Structure of 5(6)-carboxyfluorescein. 















Figure 6.3 MALDI-TOF spectrum of chemically synthesized carboxyfluorescein-labeled 
amylin. 
 
As ascertained by TEM analysis, amylin fibrils emanating from carboxy-amy exhibited a 
similar morphology to fibrils formed by unmodified amylin (Figure 6.4). 
 
  
Figure 6.4 Comparison of the amyloidogenic potential of chemically synthesized amylin (A) 
and carboxy-amy (B) by TEM. Disaggregated peptide samples were prepared in 10 mM 
sodium phosphate buffer, pH 7.4 containing 50 mM NaCl to a final concentration of 30 µM. 
Representative electron micrographs of each sample is shown after an incubation time of 60 
minutes at 37C. Scale bars represent 200 nm. 
A B
Chapter 6  Research Results IV 
 
117 
Confocal microscopy imaging analysis confirmed that the carboxyfluorescein fluorophore 
was stable over the experimental duration, in that no photo-beaching was evident as the 




Figure 6.5 Confocal microscopy of RIN-5F cells exposed to carboxyfluorescein only (2.54 
μM, equivalent to the amount of carboxyfluorescein present in 30 μM of carboxy-amy) at the 
start of the experiment and after three hours. The mean fluorescence intensity at 5 mins is 
14.5 ± 3.0 and at 185 mins is 14.2 ± 3.0. The fluorescent intensity of carboxyfluorescein at the 
two time intervals were observed to be statically similar (p > 0.05). It is thus evident that the 
carboxyfluorescein label does not undergo photo-bleaching and neither does it interact with 
the cells. Each image represents the equatorial region of the cells and are overlays of the green 
fluorescent channel and the simultaneously obtained DIC image. Scale bars represent 200 μm. 
Statistical analysis (Welch’s unpaired t-test) was performed using GraphPad InStat version 3 
(GraphPad Software, U.S.A). 
 
Analysis of confocal microscopy generated images seem to suggest that aggregates of 
carboxy-amy that are indicated by colored (yellow, white, blue, red and pink) arrows strongly 
interacts with the extracellular face of the RIN-5F plasma membrane (Figure 6.6). This is 
evidenced in that aggregates remain associated with the plasma membrane although the 
cellular morphology in certain instances changes markedly over the three hour duration of the 
experiment. It is noteworthy that carboxy-amy cannot be observed intracellularly. 
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35 mins 5 mins 95 mins 65 mins 
185 mins 155 mins 125 mins 
 
 
Figure 6.6 Carboxy-amy interaction with the cell membrane of RIN-5F cells at 30 minute intervals as determined by confocal microscopy. Each 
image represents the equatorial region of the cells and is an overlay of the green fluorescent channel and the simultaneously obtained DIC image. 
Different colored arrows are used to indicate the cellular localization of amylin over time. Scale bars represent 200 μm. 
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NTA of samples containing carboxyfluorescein only, illustrated a background fluorescence 
without any discernible aggregates being observed at all time points. The presence of a faint 
background indicates that the fluorophore is present but does not form aggregates greater than 
30 nm in size and thus cannot be detected since the size range for NTA is 30-1000 nm.[56] 
 
During NTA, resuspension, injection and equilibration times resulted in a time lapse of 
approximately ten minutes, thereby rendering analysis of a zero time-point impractical. As 
can be seen in Figure 6.7 (plot A), the predominant size of carboxy-amy at the ten minute 
time-point is between 40-90 nm, reaching a concentration greater than 2 x 107 aggregates/mL. 
Other peaks represent aggregates that were in the size range 90-260 nm and which occurred at 
concentrations between 0.5 x 107 aggregates/mL and 1 x 107 aggregates/mL. In addition 
another predominant peak represents an aggregate cohort with a size of approximately 510 
nm and concentration of approximately 0.7 x 107 aggregates/mL. After three hours (Figure 
6.7, plot B), the concentration of 100-170 nm aggregates were below 0.5 x 107 aggregates/mL 
whilst the predominant peaks representing aggregates in the 170-250 nm and 250-360 nm 
ranges were present at concentrations above 1 x 107 aggregates/mL, indicating that the 
smaller sized aggregates (40-90 nm and 90-170 nm) that were present at the ten minute time-
point have now grown into larger particles (170-250 nm and 250-360 nm). Interestingly, the 
observed 510 nm peak at the ten minute interval is not evident after three hours. Rather, the 
emergence of two new peaks (360-520 nm and 640-850 nm) is observed. Growth medium 
that was recovered from the confocal microscopy experiment (Figure 6.7, plot C) and which 
was subjected to NTA revealed a carboxy-amy aggregate size distribution profile that was 
similar to that of the carboxy-amy sample alone after an incubation period of three hours 
(Figure 6.7, plot B). However, a higher concentration of particles in all size ranges except the 
270-400 nm range was observed in the sample recovered from the confocal microscopy 
experiment.  
 




Figure 6.7 NTA size distribution profile of disaggregated carboxy-amy (30 μM) in 10 mM 
sodium phosphate buffer, pH 7.4 containing 50 mM NaCl after incubation at 37C for 10 
minutes (A) and 180 minutes (B). (C) NTA size distribution profile of the carboxy-amy 
sample that was recovered from the completed confocal microscopy experiments. Video 
recordings (duration of 60 seconds) of each sample were taken for NTA using the single 
shutter and gain mode. 
 
6.5 Discussion 
As mentioned previously, it is widely accepted that the aggregated form of amylin is linked to 
the destruction of pancreatic beta cells. It is therefore prudent that technology is developed 
that provides a closer insight into the interaction of amylin aggregates with cellular structures. 
This awareness may in part contribute to the successful design of an effective inhibitor of 
amylin aggregation and cytotoxicity. Up until now the cellular tracking of amylin aggregates 
has been reliant on indirect labeling strategies that are compromised by non-specific binding 
interactions and interference of amylin-amylin interactions that precludes reliable data 
interpretation. The present study was initiated in an attempt to visualize the in vitro 
interaction of amylin aggregates with a cultured mammalian cell line using a confocal 
microscopy-based fluorescent approach. 
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To negate any possibility of incorrect data interpretation, it was deemed critical that control 
experiments using only carboxyfluorescein be performed and the amyloidogenic nature of 
carboxy-amy be compared to unmodified amylin. In control confocal microscopy experiments 
using only carboxyfluorescein, it was observed that the fluorophore does not interact with the 
cells and neither does it aggregate over the duration of the experiment. This was further 
substantiated by NTA of samples containing carboxyfluorescein only as no particles were 
detected at all time-points. It is thus noteworthy that all observations on carboxy-amy reported 
in this study represent the modified peptide and are not due to interactions resulting from the 
carboxyfluorescein tag alone. In addition, carboxy-amy was shown via TEM analysis to form 
typical amyloid fibrils that were comparable to those formed by unmodified amylin. It can 
thus be suggested that attachment of the fluorophore did not impact negatively on the 
amyloidogenic nature of amylin. Thus it may be suggested that the fluorescent labeling 
approach as employed in the current study be considered as a viable option to investigate the 
aggregation dynamics of amylin. 
 
Confocal microscopy imaging resolved that carboxy-amy aggregates specifically interact with 
the cell membrane of RIN-5F cells. It was also interesting to note that the interactions were 
limited to certain regions of the membrane as opposed to a more global interactive pattern. As 
mentioned previously, the carboxy-amy aggregates in certain instances remained strongly 
associated with the membrane whilst it shifted during cellular morphological changes. The 
latter observation is suggestive of a physical interaction between the two entities. This is 
supportive of previous studies which found that amylin associates with synthetic membranes, 
GUVs, or cell membranes.[33, 36-39, 41-43, 57, 58] Possible reasons for amylin interacting 
with the cell membrane have previously been proposed with studies suggesting that either 
hydrophobic or electrostatic interactions are responsible for this association.[36-39, 41-43, 57, 
58] Hydrophobic interactions are possible since amylin has more hydrophobic R-groups in its 
constituent amino acids than hydrophilic R-groups, thus allowing amylin to interact with the 
non-polar membranes, whilst electrostatic interactions between positively charged amino 
acids and the negatively charged membrane could also facilitate amylin-membrane 
association. Reviews by Stefani (2007 and 2010) extensively describe the role of membrane 
interaction with amyloidogenic peptides and the subsequent cytotoxicity.[59, 60] Amylin has 
also been shown to bind to heparin sulfate proteoglycans that are present in the basement 
membrane of pancreatic beta cells. The latter binding interaction could also apply to the 
interaction of carboxy-amy aggregates with RIN-5F cells in this study.[61] 
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Understanding the fine details of the interaction of amylin aggregates with cellular 
membranes has the potential to unravel the mechanism of amylin-induced cytotoxicity. One 
hypothesis supported by experimental findings, is that amylin mediates cytotoxicity by 
binding to and initiating pore formation in cellular membranes thus compromising its 
integrity.[7, 8, 62] Another possible amyloidogenic protein-mediated mechanism of 
cytotoxicity, is that the protein monomer or oligomer would interact with the lipid bilayer of 
the cell membrane and extract lipids from the membrane during the aggregation process 
thereby resulting in membrane damage.[41] This is especially significant since it was reported 
that a high fat intake or change in lipid metabolism was necessary for fibril formation.[63, 64] 
A subsequent report suggested that these latter events would result in type II diabetes.[36] In 
addition, examination of islets revealed that membranes in close proximity to the amyloid 
deposits appeared to be damaged which could disrupt membrane fluidity and affect the uptake 
of glucose by the pancreatic beta cells, thereby leading to cytotoxicity.[35] It was also 
previously reported that amylin embeds itself in the basement membrane, forming an 
envelope around the intra-islet capillary endothelium which may have a negative effect on 
absorption of nutrients and hence could facilitate toxicity.[34] A more recent study has also 
shown that amylin interacts with and damages synthetic membranes of giant unilamellar 
vesicles.[43] Based on the confocal microscopy observations described in this study, it will be 
quite prudent to design an inhibitor of amylin-plasma membrane association since there is 
only one reported study to date that has used a molecule of this kind (e.g. rifampicin) to 
decrease amylin-mediated cytotoxicity.[15] 
 
Carboxy-amy aggregation was also followed over time using NTA and it was observed that 
the concentration and size of aggregates increases over the three hour duration of the 
experiment. NTA also illustrated that the size distribution profiles of aggregates present in the 
samples recovered from the confocal microscopy experiment were similar to that of freshly 
prepared samples. However, it was noted that the concentration of aggregates in the sample 
recovered from the confocal microscopy experiment was higher than the concentration of 
aggregates that formed in the carboxy-amy sample that was not exposed to cellular 
interaction. This finding is similar to that reported by Jaysinghe and Langen (2005) whom 
also reported that amylin aggregates much more rapidly in the presence of synthetic 
membranes containing phosphatidylserine.[37] In the presence of RIN-5F cells, the 
predominant size ranges of amylin aggregates that formed were observed to be 130-270 nm, 
270-400 nm, 400-600 nm and 600-800 nm. This data is consistent with a previous study that 
used total internal reflection fluorescence microscopy and reported that amylin aggregates 
spanned a size range between 200 nm and 560 nm.[65] 
 




This study has demonstrated for the first time that labeling of full length human amylin with 
the fluorescent tag carboxyfluorescein does not alter the aggregating potential of the peptide. 
Thus, it can be suggested that this fluorescent-labeled peptide could be used to monitor the 
aggregation dynamics of amylin and hence for screening potential inhibitors of amylin 
aggregation and possibly even inhibitors of amylin-mediated cytotoxicity. In addition it was 
demonstrated that amylin interacts with the cell membrane which supports the already 
proposed hypothesis that amylin-mediated cytotoxicity results from membrane disruption.  
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7. GENERAL DISCUSSION AND CONCLUSION 
 
7.1 GENERAL DISCUSSION AND CONCLUSION 
To avoid the use of expensive pseudoproline derivatives in the chemical synthesis of full 
length human amylin [1-6], a microwave-assisted solid phase peptide synthetic strategy that 
makes use of the ChemMatrix (CM) resin and triple couplings for problematic amino acids 
was developed. As previously reported for the synthesis of other hydrophobic and highly 
structured peptides [7-9], the polyethyleneglycol-based resin (CM) resin was observed to be 
suitable for amylin synthesis. In addition, it was shown that oxidation with iodine is effective 
in the formation of the disulfide bridge between residues two and seven of full length amylin. 
Moreover, the use of purified unoxidized amylin in the afore-mentioned oxidation reaction 
yielded amylin with the requisite secondary disulfide structure without the need for further 
purification. The chemically synthesized amylin yielded in this study displayed a higher 
purity than two other commercially available amylin products. 
 
After a comprehensive literature review encompassing all reports on the amyloidogenic 
properties of amylin, distinct regions of the amino acid sequence of human amylin were 
identified as potential inhibitors of amylin aggregation. In this regard, non-methylated and N-
methylated amylin derivatives were synthesized and it was established that the NTAT and 
ST(N-Me)NV(N-Me)G(N-Me)S(N-Me) amylin derivatives were attractive candidates in their 
capability to reduce the formation of amylin  fibrils. In support of previous findings [10-16], 
data generated in this study indicates that the fibrillar form of amylin is non-toxic since all the 
non-methylated amylin derivatives were found to be effective inhibitors of amylin-mediated 
cytotoxicity, with STNVGS demonstrating superior inhibitory activity. Of significance, the 
only N-methylated amylin derivative that reduced amylin-induced cytotoxicity [ST(N-
Me)NV(N-Me)G(N-Me)S(N-Me)] is homologous to the most potent peptide inhibitor of 
amylin-induced cytotoxicity. Consequently, it can be suggested that this region of amylin 
plays a key role in fibrillogenesis. 
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Although cytotoxicity assays provides an invaluable insight into the potential of molecules as 
inhibitors of amylin-mediated cytotoxicity, the costly and time-consuming nature of this cell-
based assay system warrants development of a cell-free approach. To this end, surface 
plasmon resonance (SPR), dynamic light scattering (DLS) and nanoparticle tracking analysis 
(NTA) were evaluated. No data was generated from DLS studies due to its limitation in the 
analysis of poly-disperse samples, and SPR-generated data could not be correlated to 
previously established cytotoxicity results since the binding of an inhibitor to amylin does not 
necessarily specify its inhibitory potential.[17] However, it was found that NTA could 
monitor the change in size of amylin aggregates as it progressed over time and the 
concentration of certain sized aggregates could be correlated to cytotoxicity data. On further 
optimization of NTA, this technique seems to be an attractive option as a possible cell-free 
assay that can be used to reliably screen inhibitors of amylin-induced cytotoxicity. 
 
Furthermore it was also demonstrated that SPR analysis does allow for the quantification of 
amylin association and dissociation kinetics (association constant (ka) = 28.7 ± 5.1 M
-1s-1 and 
dissociation constant (kd) = 2.8 ± 0.6 x 10
-4 s-1). Of note, amylin association kinetics were 
similar to that reported for Aβ whilst it was evident that Aβ dissociates faster than amylin [18, 
19], suggesting that even though amyloidogenic peptides share similarities in their structural 
properties [20], the intricacies of fibril formation are dissimilar. 
 
A carboxyfluorescein modification of amylin was demonstrated to have no effect on the 
fibrillogenic nature of the peptide. This modified form of amylin thus provided a direct 
approach to gain insight into the cellular localization of amylin. As previously reported, 
amylin was observed to associate with the plasma membrane [21, 22], however the strategy 
used herein negated any effects of extraneous dyes that have been previously shown to reduce 
amylin-amylin and amylin-cell interactions. Although it has been previously suggested that 
amylin exerts its toxic effect by binding to the plasma membrane, possibly resulting in 
membrane disruption and also activating signaling pathways that are involved in apoptosis 
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Further prospects arising from this study that warrant further investigation can be summarized 
as follows: 
 The biodegradability of ST(N-Me)NV(N-Me)G(N-Me)S(N-Me) should be ascertained 
and in vivo testing performed to establish their potential as effective therapeutic agents for 
type II diabetes. 
 
 Peptoids homologous to amylin and in particular its 29-34 region can also be synthesized 
and evaluated as potential inhibitors of amylin-mediated cytotoxicity.  
 
 Since amylin association with the plasma membrane facilitates amylin-induced 
cytotoxicity, therapeutic molecules that specifically target this interaction can be designed 
as potential therapeutic agents for type II diabetes. 
 
 It is also recommended that more extensive studies using NTA be implemented to 
ascertain the suitability of this cell-free approach as an efficient screening technique for 
potential inhibitors of amylin-mediated cytotoxicity. 
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